1
|
Amaducci S, Colonna N, Cosentino L, Cristallo S, Finocchiaro P, Krtička M, Massimi C, Mastromarco M, Mazzone A, Maugeri EA, Mengoni A, Roederer IU, Straniero O, Valenta S, Vescovi D, Aberle O, Alcayne V, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Caballero-Ontanaya L, Calviño F, Calviani M, Cano-Ott D, Casanovas A, Cerutti F, Chiaveri E, Cortés G, Cortés-Giraldo MA, Damone LA, Davies PJ, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domínguez B, Ferrari A, Furman V, Göbel K, Garg R, Gawlik-Ramięga A, Gilardoni S, Gonçalves IF, González-Romero E, Guerrero C, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Junghans A, Käppeler F, Kadi Y, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Kurtulgil D, Ladarescu I, Lederer-Woods C, Leeb H, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Mastinu P, Mendoza E, Michalopoulou V, Milazzo PM, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, Quesada JM, Ramos-Doval D, Rauscher T, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith AG, Sosnin NV, Sprung P, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Thomas T, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright T, Žugec P. Measurement of the ^{140}Ce(n,γ) Cross Section at n_TOF and Its Astrophysical Implications for the Chemical Evolution of the Universe. Phys Rev Lett 2024; 132:122701. [PMID: 38579210 DOI: 10.1103/physrevlett.132.122701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 11/09/2023] [Accepted: 01/31/2024] [Indexed: 04/07/2024]
Abstract
^{140}Ce(n,γ) is a key reaction for slow neutron-capture (s-process) nucleosynthesis due to being a bottleneck in the reaction flow. For this reason, it was measured with high accuracy (uncertainty ≈5%) at the n_TOF facility, with an unprecedented combination of a high purity sample and low neutron-sensitivity detectors. The measured Maxwellian averaged cross section is up to 40% higher than previously accepted values. Stellar model calculations indicate a reduction around 20% of the s-process contribution to the Galactic cerium abundance and smaller sizeable differences for most of the heavier elements. No variations are found in the nucleosynthesis from massive stars.
Collapse
Affiliation(s)
- S Amaducci
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - N Colonna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - L Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - S Cristallo
- Istituto Nazionale di Astrofisica - Osservatorio Astronomico d'Abruzzo, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Perugia, Italy
| | | | - M Krtička
- Charles University, Prague, Czech Republic
| | - C Massimi
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Italy
| | - M Mastromarco
- European Organization for Nuclear Research (CERN), Switzerland
| | - A Mazzone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Consiglio Nazionale delle Ricerche, Bari, Italy
| | - E A Maugeri
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - A Mengoni
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile (ENEA), Italy
| | - I U Roederer
- Department of Physics, North Carolina State University, Raleigh, Norh Carolina 27695, USA
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements (JINA-CEE), USA
| | - O Straniero
- Istituto Nazionale di Astrofisica - Osservatorio Astronomico d'Abruzzo, Italy
- INFN Sezione Napoli, Napoli, Italy
| | - S Valenta
- Charles University, Prague, Czech Republic
| | - D Vescovi
- Istituto Nazionale di Astrofisica - Osservatorio Astronomico d'Abruzzo, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Perugia, Italy
| | - O Aberle
- European Organization for Nuclear Research (CERN), Switzerland
| | - V Alcayne
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Spain
| | | | - L Audouin
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, F-91406 Orsay Cedex, France
| | - V Babiano-Suarez
- Instituto de Física Corpuscular, CSIC - Universidad de Valencia, Spain
| | - M Bacak
- European Organization for Nuclear Research (CERN), Switzerland
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
- CEA Irfu, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Barbagallo
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- European Organization for Nuclear Research (CERN), Switzerland
| | - S Bennett
- University of Manchester, United Kingdom
| | - E Berthoumieux
- CEA Irfu, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - J Billowes
- University of Manchester, United Kingdom
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | - A Brown
- University of York, United Kingdom
| | - M Busso
- Istituto Nazionale di Fisica Nucleare, Sezione di Perugia, Italy
- Dipartimento di Fisica e Geologia, Università di Perugia, Italy
| | - M Caamaño
- IGFAE-Universidade de Santiago de Compostela, Spain
| | | | - F Calviño
- Universitat Politècnica de Catalunya, Spain
| | - M Calviani
- European Organization for Nuclear Research (CERN), Switzerland
| | - D Cano-Ott
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Spain
| | | | - F Cerutti
- European Organization for Nuclear Research (CERN), Switzerland
| | - E Chiaveri
- European Organization for Nuclear Research (CERN), Switzerland
- University of Manchester, United Kingdom
| | - G Cortés
- Universitat Politècnica de Catalunya, Spain
| | | | - L A Damone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Dipartimento Interateneo di Fisica, Università degli Studi di Bari, Italy
| | - P J Davies
- University of Manchester, United Kingdom
| | - M Diakaki
- European Organization for Nuclear Research (CERN), Switzerland
- National Technical University of Athens, Greece
| | - M Dietz
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - C Domingo-Pardo
- Instituto de Física Corpuscular, CSIC - Universidad de Valencia, Spain
| | - R Dressler
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - Q Ducasse
- Physikalisch-Technische Bundesanstalt (PTB), Bundesallee 100, 38116 Braunschweig, Germany
| | - E Dupont
- CEA Irfu, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - I Durán
- IGFAE-Universidade de Santiago de Compostela, Spain
| | - Z Eleme
- University of Ioannina, Greece
| | | | - A Ferrari
- European Organization for Nuclear Research (CERN), Switzerland
| | - V Furman
- Affiliated with an institute or an international laboratory covered by a cooperation agreement with CERN
| | - K Göbel
- Goethe University Frankfurt, Germany
| | - R Garg
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | | | - S Gilardoni
- European Organization for Nuclear Research (CERN), Switzerland
| | | | - E González-Romero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Spain
| | | | - F Gunsing
- CEA Irfu, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - S Heinitz
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - J Heyse
- European Commission, Joint Research Centre (JRC), Geel, Belgium
| | | | - A Junghans
- Helmholtz-Zentrum Dresden-Rossendorf, Germany
| | - F Käppeler
- Karlsruhe Institute of Technology, Campus North, IKP, 76021 Karlsruhe, Germany
| | - Y Kadi
- European Organization for Nuclear Research (CERN), Switzerland
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - I Knapová
- Charles University, Prague, Czech Republic
| | - M Kokkoris
- National Technical University of Athens, Greece
| | - Y Kopatch
- Affiliated with an institute or an international laboratory covered by a cooperation agreement with CERN
| | | | - I Ladarescu
- Instituto de Física Corpuscular, CSIC - Universidad de Valencia, Spain
| | - C Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - H Leeb
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | | | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - D Macina
- European Organization for Nuclear Research (CERN), Switzerland
| | - A Manna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Italy
| | - T Martínez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Spain
| | - A Masi
- European Organization for Nuclear Research (CERN), Switzerland
| | - P Mastinu
- INFN Laboratori Nazionali di Legnaro, Italy
| | - E Mendoza
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Spain
| | - V Michalopoulou
- European Organization for Nuclear Research (CERN), Switzerland
- National Technical University of Athens, Greece
| | - P M Milazzo
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
| | - F Mingrone
- European Organization for Nuclear Research (CERN), Switzerland
| | - J Moreno-Soto
- CEA Irfu, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Musumarra
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, Italy
- Department of Physics and Astronomy, University of Catania, Italy
| | - A Negret
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Romania
| | - R Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Bundesallee 100, 38116 Braunschweig, Germany
| | | | - A Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Romania
| | | | - A Pavlik
- University of Vienna, Faculty of Physics, Vienna, Austria
| | | | - C Petrone
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Romania
| | - L Piersanti
- Istituto Nazionale di Astrofisica - Osservatorio Astronomico d'Abruzzo, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Perugia, Italy
| | - E Pirovano
- Physikalisch-Technische Bundesanstalt (PTB), Bundesallee 100, 38116 Braunschweig, Germany
| | | | | | | | - D Ramos-Doval
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, F-91406 Orsay Cedex, France
| | - T Rauscher
- Department of Physics, University of Basel, Switzerland
- Centre for Astrophysics Research, University of Hertfordshire, United Kingdom
| | | | - D Rochman
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - C Rubbia
- European Organization for Nuclear Research (CERN), Switzerland
| | - M Sabaté-Gilarte
- European Organization for Nuclear Research (CERN), Switzerland
- Universidad de Sevilla, Spain
| | - A Saxena
- Bhabha Atomic Research Centre (BARC), India
| | - P Schillebeeckx
- European Commission, Joint Research Centre (JRC), Geel, Belgium
| | - D Schumann
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - A Sekhar
- University of Manchester, United Kingdom
| | - A G Smith
- University of Manchester, United Kingdom
| | - N V Sosnin
- University of Manchester, United Kingdom
| | - P Sprung
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | | | - G Tagliente
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - J L Tain
- Instituto de Física Corpuscular, CSIC - Universidad de Valencia, Spain
| | | | - L Tassan-Got
- European Organization for Nuclear Research (CERN), Switzerland
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, F-91406 Orsay Cedex, France
- National Technical University of Athens, Greece
| | - Th Thomas
- Goethe University Frankfurt, Germany
| | | | - A Tsinganis
- European Organization for Nuclear Research (CERN), Switzerland
| | - J Ulrich
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - S Urlass
- European Organization for Nuclear Research (CERN), Switzerland
- Helmholtz-Zentrum Dresden-Rossendorf, Germany
| | - G Vannini
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Italy
| | - V Variale
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - P Vaz
- Instituto Superior Técnico, Lisbon, Portugal
| | - A Ventura
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - V Vlachoudis
- European Organization for Nuclear Research (CERN), Switzerland
| | - R Vlastou
- National Technical University of Athens, Greece
| | - A Wallner
- Australian National University, Canberra, Australia
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, United Kingdom
| | - P Žugec
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
2
|
Kim AY, Woo W, Saxena A, Tanidir IC, Yao A, Kurniawati Y, Thakur V, Shin YR, Shin JI, Jung JW, Barron DJ. Treatment of hypoplastic left heart syndrome: a systematic review and meta-analysis of randomised controlled trials. Cardiol Young 2024; 34:659-666. [PMID: 37724575 DOI: 10.1017/s1047951123002986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
BACKGROUND This meta-analysis aimed to consolidate existing data from randomised controlled trials on hypoplastic left heart syndrome. METHODS Hypoplastic left heart syndrome specific randomised controlled trials published between January 2005 and September 2021 in MEDLINE, EMBASE, and Cochrane databases were included. Regardless of clinical outcomes, we included all randomised controlled trials about hypoplastic left heart syndrome and categorised them according to their results. Two reviewers independently assessed for eligibility, relevance, and data extraction. The primary outcome was mortality after Norwood surgery. Study quality and heterogeneity were assessed. A random-effects model was used for analysis. RESULTS Of the 33 included randomised controlled trials, 21 compared right ventricle-to-pulmonary artery shunt and modified Blalock-Taussig-Thomas shunt during the Norwood procedure, and 12 regarded medication, surgical strategy, cardiopulmonary bypass tactics, and ICU management. Survival rates up to 1 year were superior in the right ventricle-to-pulmonary artery shunt group; this difference began to disappear at 3 years and remained unchanged until 6 years. The right ventricle-to-pulmonary artery shunt group had a significantly higher reintervention rate from the interstage to the 6-year follow-up period. Right ventricular function was better in the modified Blalock-Taussig-Thomas shunt group 1-3 years after the Norwood procedure, but its superiority diminished in the 6-year follow-up. Randomised controlled trials regarding medical treatment, surgical strategy during cardiopulmonary bypass, and ICU management yielded insignificant results. CONCLUSIONS Although right ventricle-to-pulmonary artery shunt appeared to be superior in the early period, the two shunts applied during the Norwood procedure demonstrated comparable long-term prognosis despite high reintervention rates in right ventricle-to-pulmonary artery shunt due to pulmonary artery stenosis. For medical/perioperative management of hypoplastic left heart syndrome, further randomised controlled trials are needed to deliver specific evidence-based recommendations.
Collapse
Affiliation(s)
- A Y Kim
- Division of Pediatric Cardiology, Department of Pediatrics, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
- Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
| | - W Woo
- Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - A Saxena
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
| | - I C Tanidir
- Department of Pediatric Cardiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
| | - A Yao
- Department of Health Service Promotion, University of Tokyo, Japan
| | - Y Kurniawati
- Department of Pediatric Cardiology, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
| | - V Thakur
- Department of Pediatrics, Labatt Family Heart Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Y R Shin
- Department of Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea
| | - J I Shin
- Department of Pediatrics, Labatt Family Heart Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
- Severance Underwood Meta-research Center, Institute of Convergence Science, Yonsei University, Seoul, South Korea
| | - J W Jung
- Division of Pediatric Cardiology, Department of Pediatrics, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
- Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
| | - D J Barron
- Division of Cardiovascular Surgery, Department of Surgery, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
3
|
Yarlagadda S, Kutuk T, Saxena A, Roy M, Tolakanahalli RP, Appel H, La Rosa de Los Rios AF, Tom MC, Hall MD, Wieczorek DJ, Lee YC, McDermott MW, Ahluwalia M, Gutierrez A, Mehta MP, Kotecha R. Stereotactic Radiosurgery for Small Intact Brain Metastasis: A Comparative Evaluation of 3 Different Single Fraction Prescription Doses. Int J Radiat Oncol Biol Phys 2023; 117:e159-e160. [PMID: 37784753 DOI: 10.1016/j.ijrobp.2023.06.989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) While single-fraction stereotactic radiosurgery (SRS) in the treatment of small brain metastases (SBM, ≤ 2 cm) is well established, prescription dosing varies considerably across institutions and clinical trials. The choice of prescription dose is a delicate balance between local failure (LF) and radiation necrosis (RN) risks. In the modern era, historically-established dosing thresholds may no longer be applicable. To evaluate the impact of prescription dose on outcomes, we performed a comparative analysis of patients with SBM treated with definitive SRS using three different prescriptions, at a single tertiary institution. MATERIALS/METHODS Consecutive patients with intact SBM treated with SRS from January 2017 and December 2021 were analyzed. Baseline patient characteristics and dosing parameters were abstracted from the medical record. To limit the integral brain dose when treating multiple brain metastases, the institutional practice was to reduce prescription dose as the total number of lesions increased (i.e., 24 Gy for ≤10 lesions, 22 Gy for 11-20, and 20 Gy for >20). A per lesion analysis, where each lesion was followed from the date of SRS to the last follow-up, was conducted with primary endpoints of LF and RN. Gray's test was used to compare the cumulative incidence of the LF and RN, with death as a competing risk. Factors affecting LF were analyzed using Cox hazard regression analysis. RESULTS A total of 1318 SBM in 250 patients received SRS and met the inclusion criteria. The median age was 62 years (range: 18-90), median KPS was 90 (range: 50-100) and 66% were female. The most common primary tumors were lung (55.5%) and breast cancers (26.4%). With a median follow-up of 12 months, 136 (11%) LF in 44 patients and 70 (5.7%) RN events in 46 patients occurred. The actuarial 1-year cumulative rate of LF was lower in lesions treated with 24 Gy (6.4%, 95% CI: 4.7-8.6%) or 22 Gy (5.8%, 95% CI: 3.7-8.7%) compared to 20 Gy (15.4%, 95% CI: 10.9-20.5%) (p<0.01). 22 Gy and 24 Gy prescription doses were associated with a 44% and 52% reduction in risk in LF compared to 20 Gy (HR: 0.56; 95% CI: 0.36-0.9; p = 0.01 and HR: 0.48; 95% CI: 0.31-0.74; p<0.01, respectively). In a subset analysis of radiosensitive tumors, 1-year LF rate was still lower with 24 Gy (7.4%, 95% CI: 5.3-9.9%) and 22 Gy (6.1%, 95% CI: 3.7-9.4%) than 20 Gy (15.7%, 95% CI: 11.2-21%) (p = 0.01). The cumulative 1-year RN rate numerically declined with dose, but was not statistically significantly different, with 3.6% (95% CI: 2.3-5.3%) for 24 Gy, 2.6% (95% CI: 1.3-4.8%) for 22 Gy and 1.4% (95% CI: 0.4-3.7%) for 20 Gy. CONCLUSION Patients treated with single fraction SRS to intact SBM were at increased risk of LF with prescription doses of 20 Gy compared to 22-24 Gy, without an increased risk of RN. Even in patients with radiosensitive histologies, higher LF rates were still observed following 20 Gy compared to 22-24 Gy.
Collapse
Affiliation(s)
- S Yarlagadda
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - T Kutuk
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - A Saxena
- Department of Biostatistics, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M Roy
- Department of Biostatistics, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - R P Tolakanahalli
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - H Appel
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - A F La Rosa de Los Rios
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M C Tom
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M D Hall
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - D J Wieczorek
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - Y C Lee
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - M W McDermott
- Department of Neurosurgery, Miami Neuroscience Institute, Baptist Health South Florida, Miami, FL
| | - M Ahluwalia
- Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - A Gutierrez
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Herbert Wertheim College of Medicine, Florida International University, Miami, FL
| | - M P Mehta
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - R Kotecha
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| |
Collapse
|
4
|
Kutuk T, Yarlagadda S, Tolakanahalli RP, Roy M, Saxena A, Hall MD, La Rosa A, Tom MC, Wieczorek DJ, Lee Y, Appel H, McDermott MW, Ahluwalia M, Gutierrez A, Mehta MP, Kotecha R. A Comparison of Local Failure and Necrosis Following Different Radiosurgery Strategies for Large Brain Metastases. Int J Radiat Oncol Biol Phys 2023; 117:e121-e122. [PMID: 37784670 DOI: 10.1016/j.ijrobp.2023.06.911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Large brain metastases (LBMs) are associated with poor local control with single-fraction stereotactic radiosurgery (SRS) alone. Various alternative strategies have been developed, including fractionated SRS (FSRS) and staged SRS (SSRS) for intact LBMs, and resection with postoperative-SRS (postop-SRS) or preoperative-SRS (preop-SRS) for operable LBMs. The objective of this study is to compare local failure (LF) and radiation necrosis (RN) outcomes among these four management strategies to determine the optimal treatment paradigm. MATERIALS/METHODS Consecutive patients diagnosed with LBM (≥2 cm in maximum dimension) between July 2017 and January 2022 and treated with one of the aforementioned strategies at a single tertiary institution were evaluated. All immobilization, target contouring, margins, dose- and prescription selection followed pre-defined institutional guidelines. Primary endpoints included LF, symptomatic RN, or a composite endpoint of these two variables. Gray's test was used to compare the cumulative incidence of the LF and the composite endpoint, with death as a competing risk. RESULTS A total of 234 LBMs in 188 consecutive patients met the inclusion criteria. The median age was 65 years (range: 31-98), the median KPS was 80 (range: 50-100), and 58% were female. The most common primary tumors were lung (48%) and breast cancer (17%). The median maximum tumor diameter was 3.0 cm (range: 2.0-5.6). 47 (20%) lesions were treated with FSRS, 66 (28%) with SSRS, 74 (32%) with postop-SRS, and 47 (20%) with preop-SRS. With a median follow-up of 12 months, 22 (9%) LF and 11 (5%) RN events occurred. The 6-month and 1-year cumulative incidences of LF for the entire cohort were 5% (95% CI: 3%-9%) and 8% (95% CI: 5%-12%), respectively. The 6-month and 1-year LF rates were 4% (95% CI: 1%-13%) and 8% (95% CI: 3%-20%) for FSRS; 8% (95% CI: 3%-20%) and 8% (95% CI: 3%-20%) for SSRS; 7% (95% CI: 3%-15%) and 8% (95% CI: 3%-16%) for postop-SRS; 0 and 7% (95% CI: 2%-20%) for preop-SRS (p>0.05). The 1-year OS rates were favorable in resected patients (61% for postop-SRS and 82% for preop-SRS) compared to SRS alone strategies (45% for FSRS and 56% for SSRS) (p = 0.004). Similarly, RN events were significantly lower in resected patients treated with either bimodality approach (0 for postop-SRS and 4% for preop-SRS) than SRS standalone strategies (9% for FSRS and 8% SSRS) (p = 0.024). At 12 months, the cumulative probabilities of the composite endpoint were 13% (95% CI: 5%-25%) for FSRS, 15% (95% CI: 7%-25%) for SSRS, 9% (95% CI: 3%-17%) for postop-SRS, and 12% (95% CI: 4%-24%) for preop-SRS and not significantly different between the groups. CONCLUSION For medically operable patients with surgically resectable LBMs, a strategy of surgery and SRS, regardless of timing, is associated with favorable local control and reduced risk for RN. For unresected patients, either SSRS or FSRS is associated with similar local control, but slightly higher RN risk. Prospective comparative evaluation is warranted.
Collapse
Affiliation(s)
- T Kutuk
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - S Yarlagadda
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - R P Tolakanahalli
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - M Roy
- Department of Biostatistics, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - A Saxena
- Department of Biostatistics, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M D Hall
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - A La Rosa
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M C Tom
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - D J Wieczorek
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - Y Lee
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - H Appel
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - M W McDermott
- Department of Neurosurgery, Miami Neuroscience Institute, Baptist Health South Florida, Miami, FL
| | - M Ahluwalia
- Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - A Gutierrez
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Herbert Wertheim College of Medicine, Florida International University, Miami, FL
| | - M P Mehta
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - R Kotecha
- Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| |
Collapse
|
5
|
Moorman AR, Cambuli F, Benitez EK, Jiang Q, Xie Y, Mahmoud A, Lumish M, Hartner S, Balkaran S, Bermeo J, Asawa S, Firat C, Saxena A, Luthra A, Sgambati V, Luckett K, Wu F, Li Y, Yi Z, Masilionis I, Soares K, Pappou E, Yaeger R, Kingham P, Jarnagin W, Paty P, Weiser MR, Mazutis L, D'Angelica M, Shia J, Garcia-Aguilar J, Nawy T, Hollmann TJ, Chaligné R, Sanchez-Vega F, Sharma R, Pe'er D, Ganesh K. Progressive plasticity during colorectal cancer metastasis. bioRxiv 2023:2023.08.18.553925. [PMID: 37662289 PMCID: PMC10473595 DOI: 10.1101/2023.08.18.553925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Metastasis is the principal cause of cancer death, yet we lack an understanding of metastatic cell states, their relationship to primary tumor states, and the mechanisms by which they transition. In a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that while primary tumors largely adopt LGR5 + intestinal stem-like states, metastases display progressive plasticity. Loss of intestinal cell states is accompanied by reprogramming into a highly conserved fetal progenitor state, followed by non-canonical differentiation into divergent squamous and neuroendocrine-like states, which is exacerbated by chemotherapy and associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cancer cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues than their intestinal lineage-restricted primary tumor counterparts. We identify PROX1 as a stabilizer of intestinal lineage in the fetal progenitor state, whose downregulation licenses non-canonical reprogramming.
Collapse
|
6
|
Govindarajan S, Saxena A, Mahajan B, Mahto M. Association of serum adiponectin levels and ADIPOQ SNP rs2241766 with breast cancer risk in Indian women. J Cancer Res Ther 2023; 19:1379-1384. [PMID: 37787312 DOI: 10.4103/jcrt.jcrt_2296_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
Context Adiponectin, an adipokine, and its gene polymorphisms have been associated with breast cancer risk in various populations. Subjects and Methods In this study, we evaluated the association of the circulating levels of adiponectin and adiponectin gene polymorphism SNP rs2241766 with breast cancer and its clinicopathological characteristics in Indian women. A case-control study was carried out with 60 Ductal Infiltrating Breast Carcinoma patients and 60 age-matched healthy controls. Serum adiponectin levels were measured by ELISA. SNP genotyping was done by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. Statistical Analysis Serum adiponectin levels were compared using the Mann Whitney U test. The frequency of genotypes was compared using the Chi-square test. The odds ratio was calculated using logistic regression. Results Lower serum adiponectin level was associated with increased risk of breast cancer in postmenopausal women (OR - 7.69; 95% CI - 2.16-27.43, P = 0.002) but not in the reproductive age group women. There was no association between adiponectin levels with the TNM stage of the tumor, histopathological grade, erbB2, and ER/PR status. The SNP rs2241766 polymorphism was not associated with breast cancer risk but the mutant genotypes TG/GG was found to be significantly associated with the lower histopathological grade of the tumor (X2 (2, N = 60) = 8.62, P = 0.01). Conclusion Our results suggest that low serum adiponectin levels are associated with an increased risk of breast cancer in postmenopausal women. The TG/GG genotypes of SNP rs2241766 polymorphism were associated with a lower histological grade of the tumor.
Collapse
Affiliation(s)
- Sumitra Govindarajan
- Department of Biochemistry, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India
| | - Alpana Saxena
- Department of Biochemistry, Hamdard Institute of Medical Science and Research, Delhi, India
| | - Bhawna Mahajan
- Department of Biochemistry, GB Pant Institute of Post Graduate Medical Education and Research, Delhi, India
| | - Mala Mahto
- Department of Biochemistry, AIIMS Patna, Bihar, India
| |
Collapse
|
7
|
Ali Beg MM, Saxena A, Singh VK, Akhter J, Habib H, Raisuddin S. Modulatory role of BV6 and chloroquine on the regulation of apoptosis and autophagy in non-small cell lung cancer cells. J Cancer Res Ther 2023; 19:S0. [PMID: 37147964 DOI: 10.4103/jcrt.jcrt_816_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Aims Non-small cell lung cancer (NSCLC) is one of the aggressive tumors mostly diagnosed in the advanced stage. Therapeutic failure and drug resistance pose a major problem in NSCLC treatment primarily due to alterations in autophagy and loss of apoptosis. Therefore, the present study aimed to investigate the importance of the second mitochondria-derived activator of caspase mimetic BV6 and autophagy inhibitor chloroquine (CQ) on the regulation of apoptosis and autophagy, respectively. Subjects and Methods Study was conducted on NCI-H23 and NCI-H522 cell lines to evaluate the effect of BV6 and CQ on the transcription and translation level of LC3-II, caspase-3, and caspase-9 genes by quantitative real-time-polymerase chain reaction and western blotting techniques. Results In NCI-H23 cell line, BV6 and CQ treatments showed increased mRNA and protein expression of caspase-3, and caspase-9 compared to its untreated counterpart. BV6 and CQ treatments also caused downregulation of LC3-II protein expression compared to its counterpart. In NCI-H522 cell line, BV6 treatment showed a significantly increased expression of caspase-3 and caspase-9 mRNA and protein expression levels whereas BV6 treatment downregulated the expression level of LC3-II protein. A similar pattern was also observed in CQ treatment when compared with the respective controls. Both BV6 and CQ modulated in vitro expression of caspases and LC3-II which have critical regulatory roles in apoptosis and autophagy, respectively. Conclusions Our findings suggest that BV6 and CQ could be promising candidates in NSCLC treatment and there is a need to explore them in vivo and in clinical applications.
Collapse
Affiliation(s)
- Mirza Masroor Ali Beg
- Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India; Biochemistry, Faculty of Medicine, Ala-Too International University, Bishkek, Kyrgyzstan
| | - Alpana Saxena
- Biochemistry, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard (Hamdard University), New Delhi, India
| | | | - Juheb Akhter
- Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India
| | - Haroon Habib
- Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India
| | - Sheikh Raisuddin
- Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India
| |
Collapse
|
8
|
Dubey N, Anjum S, Saxena A, Soni D, Marothiya S, Prakash A, Bharti C. 38. Effect of Chlorhexidine Rinsed Blood Contamination on Bond Strength of Brackets Bonded with Self-etch Primer- An in Vitro Study. Mymensingh Med J 2023; 32:550-555. [PMID: 37002770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
Abstract
The present invitro type of study has done to check the effect of blood contamination & chlorhexidine combination on the bond strength of brackets bonded with self-etch primer technique. The study consisted of ninety sound human upper premolars (extracted for orthodontic purpose) fixed in a self-cure acrylic block and segregated into three groups of 30 samples each. 0.022 slot metal MBT brackets (Gemini series-3M unitek) were bonded with self-etch primer using Transbond XT composite, CA, USA and light cure for 40 seconds) on clean buccal surface. Teeth were divided into 3 groups-Group A/Control group, Group B, Group C. A computer was used to record the force applied to debond the bonded bracket in the unit of Newton. The analysis of variance indicated that there were significant differences (F value = 6.891, p value=0.002) in bond strengths between the various groups tested. The highest value of shear bond strength occurred when chlorhexidine (Group C) was used to remove the blood contamination (mean=15.874 MPa). When bonding was done in ideal condition (Group A), shear bond strength obtained was slightly lower (mean=14.497 MPa) as compared to Group C. On the other hand, lowest shear bond strength among all three groups occurred when blood contamination (Group B) was removed with water (mean=11.059 MPa). Analysis of the study showed that shear bond strength of orthodontic brackets to enamel significantly decreased during bonding with self-etch primer in blood contamination condition. Self-etch primer displayed considerably superior performance with the use of chlorhexidine instead of water to wash the blood contamination.
Collapse
Affiliation(s)
- N Dubey
- Dr Nitu Dubey, Senior Lecturer, Department of Orthodontics and Dentofacial Orthopaedics, Mithila Minority Dental College and Hospital (MMDC&H), Darbhanga, Bihar, India; E-mail:
| | | | | | | | | | | | | |
Collapse
|
9
|
Khan R, Nijhawan A, Shick C, Salazar S, Pourmoussa A, Saxena A, Hasan M, Schiro B. Abstract No. 181 Evaluation of Carotid Artery Stenosis Using 3D/4D Vessel Cast. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
|
10
|
Saxena A, Dariya SS, Chandra KP, Patil A, Kumar D, Gupta M, Singh NK, Patni B, Sheohara R, Meenakshisundaram L, Hiramath VS, Maheshwari A, Aslam M, Surajeet SK. LDL cholesterol an unmet target in diabetic, hypertensive population pan India exposing susceptive cardiovascular disorder risk. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Management and pathophysiology of diabetes and hypertension has always been the centre of research, with new insights being found consistently. CVD is the major cause of mortality in patients with type 2 diabetes and affects approximately 32.2% of people with type 2 diabetes. Southeast Asia stands out with a higher prevalence of CAD (29.4%) compared with other regions.
Purpose
The purpose of this EHR based real world study was to identify the proportion of patients with LDL-C out of control in people living with diabetes and hypertension who were under regular care of physicians. Specialized clinical care by super-specialists ensures management of specific disorders, yet risk factors for overall cardiovascular health continue to be expressed uncontrolled.
Methods
Patients reporting for routine care in 14 centers across the country were eligible to participate in the study. Patient recruitment at each site required informed consent signature, history of at least 6 months of diabetes mellitus type 2, was sequential and independent of other sites. An EMR (Medeva) integrated research proforma was created only for this study which collected data on medical history, comorbidities, diabetic complications, medications and laboratory values of relevance to the study. The recruitment started in March 2022 and ended in August 2022 (6 months).
Results
Average age of these patients was 54.36 years, and 1238 were male and 964 were female patients. Out of this sample, 1388 patients were only diabetic and 814 patients had diabetes as well as hypertension. 256 patients 44.8% patients had LDL-C within acceptable limits and the remaining 51.2% had hyperdyslipidemia. Average LDL-C value for all patients was 107.07, average LDL-C levels in only diabetic patients was 116.51, and LDL in patients with diabetes and hypertension is 90.97. In diabetes only patients, 37% patients had LDL-C under control whereas in diabetes and hypertension group 58% patients had LDL-C under control.
Conclusion
Although diabetic patients are under regular clinical care, their LDL-C values were higher in 55.2% of the patients. This is an alarming signal that calls all the stakeholders - diabetologists, researchers, educators, dieticians, policymakers, government agencies and people with diabetes must contribute towards the management of lipid profile for prevention of cardiovascular events. Also, the proportion of patients with LDL-C under control is lesser in patients who are only diabetic as compared to patients who are both diabetic and hypertensive. This finding suggests that there is either lesser focus or inadequate on lipid profile of patients who are only diabetic; more holistic management is an unprecedented requirement. More research is needed in this direction to recognize the loopholes, manage them and prevent them adequately.
Collapse
Affiliation(s)
- A Saxena
- Diabetes and Heart Center , Ludhiana , India
| | | | - K P Chandra
- Health City Hospital, Gomti Nagar, Medicine , Lucknow , India
| | - A Patil
- ARPAN POLYCLINIC, Diebetology , Mumbai , India
| | - D Kumar
- Harsha Clinic and Diabetes Center, Medicine , Lucknow , India
| | - M Gupta
- Udayaan Health Care, Medicine , Lucknow , India
| | - N K Singh
- Diabetes and Heart Research Center, Diebetology , Dhanbad , India
| | - B Patni
- Shanti Wellness Care, Medicine , Kolkatta , India
| | - R Sheohara
- Madhumeet Diabetes Center, Non Invasive Cardiology, Medicine , Raipur , India
| | | | | | - A Maheshwari
- Hind institute of Medical Science, Professor Medicine , Lucknow , India
| | - M Aslam
- Asian Hospital , Hyderabad , India
| | | |
Collapse
|
11
|
Lederer-Woods C, Aberle O, Andrzejewski J, Audouin L, Bécares V, Bacak M, Balibrea J, Barbagallo M, Barros S, Battino U, Bečvář F, Beinrucker C, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Diakaki M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik-Ramięga A, Glodariu T, Gonçalves IF, González-Romero E, Goverdovski A, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heftrich T, Heinitz S, Heyse J, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Katabuchi T, Kavrigin P, Ketlerov V, Khryachkov V, Kimura A, Kivel N, Kokkoris M, Krtička M, Leal-Cidoncha E, Leeb H, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Losito R, Macina D, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Mirea M, Montesano S, Musumarra A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rout PC, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiss C, Wolf C, Woods PJ, Wright T, Žugec P. 74 Ge( n , γ ) cross section below 70 keV measured at n_TOF CERN. Eur Phys J A Hadron Nucl 2022; 58:239. [PMID: 36514540 PMCID: PMC9734248 DOI: 10.1140/epja/s10050-022-00878-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 10/31/2022] [Indexed: 06/17/2023]
Abstract
Neutron capture reaction cross sections on 74 Ge are of importance to determine 74 Ge production during the astrophysical slow neutron capture process. We present new resonance data on 74 Ge( n , γ ) reactions below 70 keV neutron energy. We calculate Maxwellian averaged cross sections, combining our data below 70 keV with evaluated cross sections at higher neutron energies. Our stellar cross sections are in agreement with a previous activation measurement performed at Forschungszentrum Karlsruhe by Marganiec et al., once their data has been re-normalised to account for an update in the reference cross section used in that experiment.
Collapse
Affiliation(s)
- C. Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - O. Aberle
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - L. Audouin
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - V. Bécares
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M. Bacak
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - J. Balibrea
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M. Barbagallo
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - S. Barros
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - F. Bečvář
- Charles University, Prague, Czech Republic
| | | | - E. Berthoumieux
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | | | - D. Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | - M. Brugger
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M. Caamaño
- University of Santiago de Compostela, Santiago, Spain
| | - F. Calviño
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - M. Calviani
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D. Cano-Ott
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R. Cardella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A. Casanovas
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - D. M. Castelluccio
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - F. Cerutti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y. H. Chen
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - E. Chiaveri
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - N. Colonna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - G. Cortés
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | | | - L. Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - L. A. Damone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Dipartimento Interateneo di Fisica, Università degli Studi di Bari, Bari, Italy
| | - M. Diakaki
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. Domingo-Pardo
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Valencia, Spain
| | - R. Dressler
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - E. Dupont
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - I. Durán
- University of Santiago de Compostela, Santiago, Spain
| | | | - A. Ferrari
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P. Ferreira
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - V. Furman
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - K. Göbel
- Goethe University Frankfurt, Frankfurt, Germany
| | - A. R. García
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | | | - T. Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | | | - E. González-Romero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A. Goverdovski
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - E. Griesmayer
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | | | - F. Gunsing
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H. Harada
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - T. Heftrich
- Goethe University Frankfurt, Frankfurt, Germany
| | - S. Heinitz
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - J. Heyse
- European Commission, Joint Research Centre (JRC), Geel, Belgium
| | | | - E. Jericha
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - F. Käppeler
- Karlsruhe Institute of Technology, Campus North, IKP, 76021 Karlsruhe, Germany
| | - Y. Kadi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - P. Kavrigin
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - V. Ketlerov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - V. Khryachkov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - A. Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - N. Kivel
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - M. Kokkoris
- National Technical University of Athens, Athens, Greece
| | - M. Krtička
- Charles University, Prague, Czech Republic
| | | | - H. Leeb
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | | | - S. Lo Meo
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - S. J. Lonsdale
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - R. Losito
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D. Macina
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - T. Martínez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C. Massimi
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - P. Mastinu
- Istituto Nazionale di Fisica Nucleare, Sezione di Legnaro, Italy
| | - M. Mastromarco
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - F. Matteucci
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
- Dipartimento di Astronomia, Università di Trieste, Trieste, Italy
| | | | - E. Mendoza
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A. Mengoni
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
| | - P. M. Milazzo
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
| | - F. Mingrone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - M. Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | - S. Montesano
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A. Musumarra
- INFN Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Catania, Italy
| | - R. Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Bundesallee 100, 38116 Braunschweig, Germany
| | - A. Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | | | - A. Pavlik
- Faculty of Physics, University of Vienna, Vienna, Austria
| | | | - I. Porras
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- University of Granada, Granada, Spain
| | - J. Praena
- University of Granada, Granada, Spain
| | | | - K. Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T. Rauscher
- Centre for Astrophysics Research, University of Hertfordshire, Hatfield, UK
- Department of Physics, University of Basel, Basel, Switzerland
| | - R. Reifarth
- Goethe University Frankfurt, Frankfurt, Germany
| | | | - P. C. Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - C. Rubbia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J. A. Ryan
- University of Manchester, Manchester, UK
| | - M. Sabaté-Gilarte
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Universidad de Sevilla, Seville, Spain
| | - A. Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - S. Schmidt
- Goethe University Frankfurt, Frankfurt, Germany
| | - D. Schumann
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - P. Sedyshev
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | | | | | - G. Tagliente
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - J. L. Tain
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Valencia, Spain
| | | | - L. Tassan-Got
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - A. Tsinganis
- National Technical University of Athens, Athens, Greece
| | - S. Valenta
- Charles University, Prague, Czech Republic
| | - G. Vannini
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - V. Variale
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - P. Vaz
- Instituto Superior Técnico, Lisbon, Portugal
| | - A. Ventura
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - V. Vlachoudis
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R. Vlastou
- National Technical University of Athens, Athens, Greece
| | - A. Wallner
- Australian National University, Canberra, Australia
| | - S. Warren
- University of Manchester, Manchester, UK
| | - M. Weigand
- Goethe University Frankfurt, Frankfurt, Germany
| | - C. Weiss
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - C. Wolf
- Goethe University Frankfurt, Frankfurt, Germany
| | - P. J. Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - T. Wright
- University of Manchester, Manchester, UK
| | - P. Žugec
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | | |
Collapse
|
12
|
Conle né Gaudin R, Saxena A. Insertional Achilles Tendon Repair with Bioabsorbable Anchors and Suture. Muscles Ligaments Tendons J 2022. [DOI: 10.32098/mltj.04.2022.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
13
|
Oldham A, Oxborrow N, Woolfson P, Jenkins P, Gadepalli C, Ashworth J, Saxena A, Rothera M, Hendriksz C, Tol G, Jovanovic A. MPS VII - Extending the classical phenotype. Mol Genet Metab Rep 2022; 33:100922. [PMID: 36299251 PMCID: PMC9589197 DOI: 10.1016/j.ymgmr.2022.100922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 09/28/2022] [Indexed: 11/11/2022] Open
Abstract
Mucopolysaccharidosis VII (or Sly syndrome) is an autosomal recessive disorder characterised by a deficiency in the enzyme Beta-glucuronidase (GUSB). Partial degradation of glycosaminoglycans (GAGs); chondroitin sulfate (CS), dermatan sulfate (DS) and heparan sulfate (HS) results in the accumulation of these fragments in the lysosomes of many tissues, eventually leading to multisystem damage. In some cases, early diagnosis on clinical grounds alone can be difficult due to the extreme variability of the clinical presentation and disease progression. We present a case report of a 31-year-old male patient diagnosed with MPS VII at the age of 28, who multiple specialists saw without suspecting the diagnosis due to the unusual presentation. The patient presented with a history of developmental delay, scoliosis, kyphosis, corneal clouding, abnormal gait, short stature, hearing impairment, slightly coarse facial features and progressive deterioration of fine motor skills since childhood. The patient had inguinal hernia repair at around 12 months, bilateral hearing impairment with a left bone-anchored hearing aid, and spinal surgery. During spinal surveillance MPS VII was suspected by a spinal surgeon with interest in MPS, and the diagnosis confirmed with a deficiency in beta-glucuronidase in leucocytes and marginally elevated urinary GAGs. Next-generation sequencing identified two mutations in the GUSB gene (OMIM 611499), c.526C > T p.(Leu176Phe) and c.1820G > C p.(Gly607Ala). Although the patient exhibited features of the severe form of non-classical manifestations, his metabolic condition has remained reasonably stable, surviving into adulthood with only symptomatic treatment. We present the ever-expanding phenotypic spectrum of this ultra-rare disease.
Collapse
Affiliation(s)
- A. Oldham
- Mark Holland Metabolic Unit, Salford Royal NHS Foundation Trust, United Kingdom,Corresponding author.
| | | | - P. Woolfson
- Cardiology Department, Salford Royal NHS Foundation Trust, United Kingdom
| | - P. Jenkins
- North West Congenital Heart Disease Partnership, Mark Holland Metabolic Unit, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, United Kingdom
| | - C. Gadepalli
- Department of Ear, Nose and Throat, Salford Royal NHS Foundation Trust, United Kingdom
| | - J. Ashworth
- Manchester Royal Eye Hospital, Manchester Foundation NHS Trust, United Kingdom
| | - A. Saxena
- Neurosurgery, Salford Royal NHS Foundation Trust, United Kingdom
| | - M. Rothera
- Royal Manchester Children's Hospital, United Kingdom
| | - C.J. Hendriksz
- University of Pretoria, Mark Holland Metabolic Unit, Salford Royal NHS Foundation Truist, Stott Lane, Salford, M6 8HD, United Kingdom
| | - G. Tol
- Salford Royal NHS Foundation Trust, United Kingdom
| | - A. Jovanovic
- Mark Holland Metabolic Unit, Salford Royal NHS Foundation Trust, United Kingdom
| |
Collapse
|
14
|
Veluswamy R, Bhalla S, Samstein R, Marron T, Gomez J, Doroshow D, Sabari J, Shum E, Saxena A, Namakydoust A, Chachoua A, Wisnivesky J, Mandeli J, Bhardwaj N, Hirsch F, Merad M, Reddy E. 1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
15
|
Sumi MP, Guru SA, Najar IA, Mir AR, Saxena A. MO10-5 JAK2/miR-21/PTEN axis – an important pathway in JAK2(V617F) positive myeloproliferative neoplasias. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.05.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
16
|
Saxena A, Teng YKO, Collins C, England N, Leher H. POS0186 VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundVoclosporin (VCS), a novel calcineurin inhibitor, was approved in the US in January 2021 for the treatment of adult patients with active lupus nephritis (LN) in combination with background immunosuppressive therapy. The Phase 3 AURORA 1 study showed that the addition of VCS to mycophenolate mofetil (MMF) and low-dose steroids in patients with LN significantly increased rates of complete renal response at 52 weeks.ObjectivesHere we report the results of the completed continuation study, AURORA 2, which assessed the long-term safety and tolerability of VCS compared to placebo in patients with LN receiving treatment for an additional 24 months following completion of the AURORA 1 studyMethodsKey inclusion criteria for the parent AURORA 1 study included a diagnosis of biopsy-proven active LN (Class III, IV, or V ± III/IV), proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V) and estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2. Patients who completed AURORA 1 and who elected and were eligible to enter AURORA 2 continued on the same blinded therapy as at the end of AURORA 1 (either VCS or placebo twice daily in combination with MMF and low-dose steroids). Safety and tolerability were monitored, and eGFR, serum creatinine (SCr), and urine protein creatinine ratio (UPCR) were also assessed.ResultsIn total, 116 and 100 patients in the VCS and control arms enrolled in AURORA 2, with 92 (79.3%) and 73 (73.0%) patients in each respective arm receiving treatment to the end of AURORA 2. There were no unexpected safety signals in the VCS arm compared to control, with similar rates of serious adverse events reported in both arms (VCS [18.1%] vs. control [23.0%]; Table 1). Eight patients in each arm experienced serious adverse events of infection; serious coronavirus infections were observed in 2 patients in the voclosporin arm and 5 patients in the control arm. There were 4 and 2 adverse events by preferred term of renal impairment reported in the VCS and control arms, respectively, none of which were considered serious, and no reports of acute kidney injury by preferred term in either arm. There were no deaths in the VCS arm during AURORA 2; four deaths were reported in the control arm (pulmonary embolism [n=1], coronavirus infection [n=3]). Mean eGFR and SCr levels remained stable through the end of AURORA 2. The difference between the VCS and control arms in LS mean change from baseline in eGFR was 2.7 mL/min/1.73 m2 at 4 weeks following study drug discontinuation (Figure 1). The mean reductions in UPCR observed in patients treated with VCS in AURORA 1 were maintained in AURORA 2 with no increase in UPCR noted at the follow-up visit 4 weeks after study drug discontinuation.Table 1.Overall Summary of Adverse EventsControl(n=100)Voclosporin(n=116)n (%)n (%)Any AE80 (80.0)100 (86.2) Renal Impairment2 (2.0)4 (3.4) Acute Kidney Injury00Treatment-related AE21 (21.0)28 (24.1)Serious AE23 (23.0)21 (18.1)Serious Treatment-related AE2 (2.0)1 (0.9)AE Leading to Study Drug Discontinuation17 (17.0)11 (9.5)Death4 (4.0)0Treatment-related Death00Figure 1.LS Mean eGFR over TimeConclusionVoclosporin was well-tolerated over 3 years of treatment with no unexpected safety signals detected. Further, eGFR remained stable throughout the study period, and the significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. These data provide evidence of a long-term treatment benefit of VCS in patients with LN.Includes adverse events starting on or after the first dose of study drug in AURORA 2 up to 30 days after the last dose and all events of death reported during study follow-up. Adverse events were aggregated by System Organ Class and Preferred Term and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0. AE, adverse event.Disclosure of InterestsAmit Saxena Speakers bureau: Aurinia Pharmaceuticals Inc., Consultant of: Aurinia Pharmaceuticals Inc., Y.K. Onno Teng Consultant of: Aurinia Pharmaceuticals Inc., Chris Collins Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, Nicole England Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, Henry Leher Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals
Collapse
|
17
|
Guru SA, Sumi MP, Mir R, Beg MMA, Koner BC, Saxena A. Correction: Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival. BMC Cancer 2022; 22:439. [PMID: 35459155 PMCID: PMC9027819 DOI: 10.1186/s12885-022-09568-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Sameer Ahmad Guru
- Lurie Children's Hospital and Stanley Manne Children's Research Institute, Northwestern University, Chicago, IL, USA.,Department of Biochemistry, Multidisciplinary Research Unit (MRU), Maulana Azad Medical College, New Delhi, India
| | - Mamta Pervin Sumi
- Department of Inflammation and Immunity, Lerner Research Institute, Cleve Land Clinic OH, Cleveland, USA
| | - Rashid Mir
- Kingdom of Saudi Arabia, University of Tabuk, Tabuk, Saudi Arabia
| | - Mirza Masroor Ali Beg
- Faculty of Medicine and Center for Promotion of Medical Research, Faculty of Medical Sciences, Ala-Too International University, Bishek, Kyrgyzstan
| | - Bidhan Chandra Koner
- Department of Biochemistry, Hamdard Institute of Medical Science and Research (HIMSR), New Delhi, India
| | - Alpana Saxena
- Department of Biochemistry, Multidisciplinary Research Unit (MRU), Maulana Azad Medical College, New Delhi, India. .,Department of Biochemistry, Hamdard Institute of Medical Science and Research (HIMSR), New Delhi, India.
| |
Collapse
|
18
|
Guru SA, Sumi MP, Mir AR, Beg MMA, koner BC, Saxena A. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival. BMC Cancer 2022; 22:405. [PMID: 35421941 PMCID: PMC9008925 DOI: 10.1186/s12885-022-09481-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 04/04/2022] [Indexed: 12/29/2022] Open
Abstract
Abstract
Background
There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations. DNA hydroxymethylation is implicated in the development of variety of diseases. DNA hydroxymethylation in gene promoters plays important roles in disease progression, drug response and clinical outcome of various diseases. Therefore in this study, we aimed to explore the role of aberrant hydroxymethylation in promoter regions of different tumor suppressor genes in relation to CML disease progression, response to imatinib therapy and clinical outcome.
Methods
We recruited 150 CML patients at different clinical stages of the disease. Patients were followed up for 48 months and haematological/molecular responses were analysed. Haematological response was analysed by peripheral blood smear. BCR/ABL1 specific TaqMan probe based qRT-PCR was used for assessing the molecular response of CML patients on imatinib therapy. Promoter hydroxymethylation of the genes was characterized using MS-PCR.
Results
We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents. Although, cytokine signalling (SOCS1) gene was hypermethylated in advanced stages of CML and accumulated in patients with poor imatinib response, but the differences were not statistically significant. Moreover, we found hypermethylation of p14ARF, RASSF1 and p16INK4A genes and cytokine signalling gene (SOCS1) significantly associated with poor overall survival of CML patients on imatinib therapy. The results of this study are in agreement of the role of aberrant DNA methylation of different tumor suppressor genes as potential biomarkers of CML disease progression, poor imatinib response and overall clinical outcome.
Conclusion
In this study, we report that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes is a characteristic feature of CML disease progressions, defines poor imatinib respondents and poor overall survival of CML patients to imatinib therapy.
Collapse
|
19
|
Mithun T, Kevrekidis PG, Saxena A, Bishop AR. Measurement and memory in the periodically driven complex Ginzburg-Landau equation. Phys Rev E 2022; 105:034210. [PMID: 35428065 DOI: 10.1103/physreve.105.034210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 02/22/2022] [Indexed: 06/14/2023]
Abstract
In the present work we illustrate that classical but nonlinear systems may possess features reminiscent of quantum ones, such as memory, upon suitable external perturbation. As our prototypical example, we use the two-dimensional complex Ginzburg-Landau equation in its vortex glass regime. We impose an external drive as a perturbation mimicking a quantum measurement protocol, with a given "measurement rate" (the rate of repetition of the drive) and "mixing rate" (characterized by the intensity of the drive). Using a variety of measures, we find that the system may or may not retain its coherence, statistically retrieving its original glass state, depending on the strength and periodicity of the perturbing field. The corresponding parametric regimes and the associated energy cascade mechanisms involving the dynamics of vortex waveforms and domain boundaries are discussed.
Collapse
Affiliation(s)
- T Mithun
- Department of Mathematics and Statistics, University of Massachusetts, Amherst, Massachusetts 01003-4515, USA
| | - P G Kevrekidis
- Department of Mathematics and Statistics, University of Massachusetts, Amherst, Massachusetts 01003-4515, USA
| | - A Saxena
- Center for Nonlinear Studies and Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A R Bishop
- Center for Nonlinear Studies and Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
20
|
Babiano-Suarez V, Balibrea-Correa J, Caballero-Ontanaya L, Domingo-Pardo C, Ladarescu I, Lerendegui-Marco J, Tain JL, Calviño F, Casanovas A, Tarifeño-Saldivia A, Guerrero C, Aberle O, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Calviani M, Cano-Ott D, Cerutti F, Chiaveri E, Colonna N, Cortés G, CortésGiraldo MA, Cosentino L, Cristallo S, Damone LA, Davies PJ, Diakaki M, Dietz M, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domínguez B, Ferrari A, Finocchiaro P, Furman V, Göbel K, Garg R, Gawlik-Ramięga A, Gilardoni S, Gonçalves IF, González-Romero E, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Junghans A, Käppeler F, Kadi Y, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Lederer-Woods C, Leeb H, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Maugeri EA, Mazzone A, Mendoza E, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Persanti L, Petrone C, Pirovano E, Porras I, Praena J, Quesada JM, Ramos-Doval D, Rauscher T, Reifarth R, Rochman D, Romanets Y, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith AG, Sosnin NV, Sprung P, Stamatopoulos A, Tagliente G, Tassan-Got L, Thomas T, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright T, Žugec P. First 80Se(n, γ) cross section measurement with high resolution in the full stellar energy range 1 eV - 100 keV and its astrophysical implications for the s-process. EPJ Web Conf 2022. [DOI: 10.1051/epjconf/202226011026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Most elements heavier than iron have been generated in the stellar media by means of neutron capture reactions, approximately half are produced by the slow neutron capture or s-process. Radiative neutron capture cross section measurements are of fundamental importance for the study of this mechanism. In this contribution we present a brief summary on the measurement and results for the 80Se(n,γ) cross-section. The experiment was carried out at CERN n_TOF EAR1 via the time of flight (ToF) technique, using four C6D6 scintillation detectors with very fast response. More than a hundred new resonances have been analyzed for the first time with a high accuracy. The MACS obtained at kT = 8 keV is 36% smaller than the recommended value in KADo-NiS. Some of the astrophysical implications of this result are elucidated in this contribution.
Collapse
|
21
|
Parchwani D, Dholariya SJ, Takodara S, Singh R, Sharma VK, Saxena A, Patel DD, Radadiya M. Analysis of Prediagnostic Circulating Levels of Gonadotropins and Androgens with Risk of Epithelial Ovarian Cancer. J Lab Physicians 2022; 14:47-56. [PMID: 36105913 PMCID: PMC9465621 DOI: 10.1055/s-0041-1741443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background
Prevailing experimental and epidemiological evidence supports the role of circulating endogenous sex steroid hormones in the pathogenesis of ovarian carcinogenesis by dysregulation of cell differentiation, proliferation, and apoptosis but is scarce and inconclusive.
Objectives
This article evaluates the role of circulating levels of gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) and androgens (testosterone, dehydroepiandrosterone-sulfate [DHEA-S]) for the risk of epithelial ovarian cancer in a case–control approach using samples collected in advance of clinical diagnosis.
Materials and Methods
A total of 100 epithelial ovarian cancer (EOC) patients and 100 healthy female controls were consequently enrolled in this hospital-based case–control study. Serum FSH, LH, testosterone, and DHEA-S were measured based on the principle of electrochemiluminescence immunoassay. Suitable descriptive statistics were used for different variables.
Results
Median values of FSH (58.9 vs. 45.5 IU/L,
p
= 0.02) and DHEA-S (163.43 vs. 142.2 ug/dL,
p
= 0.03) were significantly high in EOC patients compared with controls. Conditional logistic regression was used to estimate the odds ratio (OR) across increasing thirds of FSH and DHEA-S concentrations, and the results revealed that the highest third tertile of FSH (> 72.6 IU/L; OR = 3.0, confidence interval [CI] = 1.24–7.29,
p
trend = 0.04) and DHEA-S (> 194.2 ug/dL; OR = 3.8, CI = 1.26–11.61,
p
trend = 0.03) were significantly associated with increased risk of ovarian cancer in postmenopausal and premenopausal women, respectively. The statistically significant trend observed for FSH in postmenopausal women, remained only for the subgroup with menopause duration greater than 10 years (OR = 5.9, CI = 1.33–26.66,
p
trend = 0.04). FSH and DHEA-S concentrations and ovarian cancer risk were internally consistent with groups defined by oral contraceptive pill use, hormone replacement therapy, and smoking. However, no evidence was found for the association between serum LH and testosterone level with the occurrence of ovarian tumorigenesis.
Conclusion
Prediagnostic circulating concentration of FSH and DHEA-S unveiled a significant positive association with augmented risk of EOC, thus might serve as a predictive marker for the susceptibility to ovarian carcinogenesis and should be added in the screening profile of EOC for early recognition and scheduling necessary interventions/management strategies.
Collapse
Affiliation(s)
- Deepak Parchwani
- Department of Biochemistry, All India Institutes of Medical Sciences, Rajkot – 360001, Gujarat, India
| | | | - Sohil Takodara
- Department of Biochemistry, Geetanjali Medical College, Udaipur, Rajasthan, India
| | - Ragini Singh
- Department of Biochemistry, All India Institutes of Medical Sciences, Rajkot – 360001, Gujarat, India
| | - Vivek Kumar Sharma
- Department of Physiology, All India Institutes of Medical Sciences, Rajkot, Gujarat, India
| | - Alpana Saxena
- Department of Biochemistry, Hamdard Institute of Medical Sciences and Research, New Delhi, India
| | - Digishaben D. Patel
- Department of Physiology, All India Institutes of Medical Sciences, Rajkot, Gujarat, India
| | - Madhuri Radadiya
- Department of Radiology, Pandit Dindayal Upadhyay Medical College, Rajkot, Gujarat, India
| |
Collapse
|
22
|
Vaswani S, Kumar V, Anand M, Kumar M, Kushwaha R, Kumar A, Saxena A, Gupta P, Kumar S. Effect of Tinospora cordifolia as phytogenic feed additive on performance parameters of sahiwal heifers. ANIM NUTR FEED TECHN 2022. [DOI: 10.5958/0974-181x.2022.00021.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
23
|
Virk S, Saxena A, Henham P, Jeremy R, Bannon P. The Impact of Pre-Existing Atrial Fibrillation on Outcomes after Percutaneous Mitral Valve Repair. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Saxena A, Shou L, Fournier M. Results of Lisfranc’s Surgery in Athletic Patients. Muscles Ligaments Tendons J 2021. [DOI: 10.32098/mltj.04.2021.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Saxena
- Department of Sports Medicine, Sutter-Palo Alto, El Camino Real, Palo Alto (CA), U.S.A
| | - L. Shou
- Reconstructive Orthopedics, Medford (NJ), U.S.A
| | - M. Fournier
- Gundersen Health System, LaCrosse (WI), U.S.A
| |
Collapse
|
25
|
Amoura Z, Furie R, Rovin B, Houssiau F, Contreras G, Malvar A, Saxena A, Yu X, Teng O, Van Paassen P, Ginzler E, Kamen D, Oldham M, Bass D, Van Maurik A, Welch M, Green Y, Ji B, Roth D. Effets du belimumab sur la fonction rénale, le contrôle global et les biomarqueurs du lupus systémique. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Abstract
Background:Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in two pivotal trials in adult patients with lupus nephritis.Previously reported results from the Phase 3 AURORA 1 study and the Phase 2 AURA-LV study showed that compared with mycophenolate mofetil (MMF) and low-dose steroids alone, the addition of voclosporin significantly increased the renal response rate and reduced proteinuria, as measured by urine protein creatinine ratio (UPCR), in patients with lupus nephritis (LN) at approximately one year of treatment (48 weeks in AURA-LV and 52 weeks in AURORA 1).Objectives:Patients that completed one year of treatment in the AURORA 1 study were eligible to enroll into the two-year, blinded, controlled extension study, AURORA 2. Here we report the first interim analysis of the ongoing AURORA 2 study.Methods:Patients completing AURORA 1 were eligible to continue the same randomized treatment of voclosporin (23.7 mg BID) or placebo, in combination with MMF (1 g BID) and low-dose oral steroids in the AURORA 2 extension. This interim analysis evaluated UPCR and estimated glomerular filtration rate (eGFR) in patients with up to two years of total treatment: one year from AURORA 1 and up to one year in AURORA 2.Results:116 patients in the voclosporin arm and 100 patients in the control arm enrolled in the extension study, of which 73 patients in the voclosporin arm and 51 patients in the control arm had received two years of treatment at the time of this interim analysis. Mean UPCR at pre-treatment (AURORA 1) baseline was 3.94 mg/mg in the voclosporin arm (n=116) and 3.87 mg/mg in the control arm (n=100). The LS mean change in UPCR from pre-treatment baseline to year two was -3.1 mg/mg for the voclosporin arm (n=73) and -2.1 mg/mg for control arm (n=51; Table 1). Mean eGFR at pre-treatment (AURORA 1) baseline was 79.6 mL/min for the voclosporin arm (n=116) and 78.9 mL/min for the control arm (n=100) and at year two, was 79.0 mL/min for the voclosporin arm (n=73) and 82.9 mL/min for the control arm (n=51). There was a small early decrease in mean eGFR in the first four weeks of treatment (in AURORA 1) after which eGFR remained stable throughout year one and year two. Additionally, there were no unexpected new AEs observed in patients who continued with voclosporin treatment compared to control-treated patients for more than one year.Table 1.UPCRControl (n=100)Voclosporin (n=116)Treatment Comparison of Voclosporin to ControlnUPCR (mg/mg)nUPCR (mg/mg)UPCR (mg/mg)p-valuePre-treatment baseline, mean1003.871163.94NCNCChange from pre-treatment baseline, LS mean Year 1100-2.4116-3.0-0.60.0080 Year 251-2.173-3.1-1.00.0004LS, least squares; NC, not calculated; UPCR, urine protein creatinine ratio.Mixed effects model for repeated measures (MMRM) analysis of LS mean change from pre-treatment baseline for UPCR included terms for baseline covariate, treatment, visit and treatment by visit interaction. Integrated results include data from pre-treatment baseline of AURORA 1, the one-year treatment period in AURORA 1 and up to a one-year treatment period in AURORA 2.Conclusion:Patients in the voclosporin treatment arm maintained meaningful reductions in proteinuria with no change in mean eGFR at two years of treatment. Additional AURORA 2 efficacy and safety data will be provided at the conclusion of the study.Disclosure of Interests:Amit Saxena: None declared, Paola Mina-Osorio Shareholder of: Aurinia Pharmaceuticals Inc., Employee of: Aurinia Pharmaceuticals Inc., Christopher Mela Shareholder of: Aurinia Pharmaceuticals Inc., Employee of: Aurinia Pharmaceuticals Inc., Vanessa Berardi Shareholder of: Aurinia Pharmaceuticals Inc., Employee of: Aurinia Pharmaceuticals Inc.
Collapse
|
27
|
Ninawe A, Guru SA, Yadav P, Masroor M, Samadhiya A, Bhutani N, Gupta N, Gupta R, Saxena A. miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia. ACS Omega 2021; 6:7711-7718. [PMID: 33778281 PMCID: PMC7992144 DOI: 10.1021/acsomega.1c00035] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 03/08/2021] [Indexed: 05/27/2023]
Abstract
MicroRNA miR-486-5p has been reported as a potential biomarker for diagnosis, prognosis, and as a therapeutic target in various cancers. In this study, we analyzed alterations in the expression of miR-486-5p in chronic Myeloid Leukemia (CML) patients. Initially, the expression of miR-486-5p was studied in the BCR-ABL1+ve CML K562 cell line by quantitative real-time polymerase chain reaction (qRT-PCR). The results indicated that the miR-486-5p expression was significantly upregulated in K562 cells after imatinib exposure, as compared to untreated K562 cells (p-value = 0.047). These observations were corroborated by a hospital-based study of the miR-486-5p expression in peripheral blood leucocytes of 36 CML patients in the chronic phase (CP) and compared with age and sex-matched healthy volunteers as control subjects. qRT-PCR-based quantification revealed significant downregulation of the miR-486-5p expression in newly diagnosed untreated CP-CML patients' samples (2-ΔCt = 13.19 ± 14.41) as compared to control samples (2-ΔCt = 254.5 ± 274.8) (p-value < 0.0001). Levels of miR-486-5p were found to be distinctly elevated in the post-imatinib treatment samples of CML patients (2-ΔCt = 469.7 ± 312.9) as compared to pre-treatment samples (p-value < 0.0001). CML patients' clinical and hematological responses to imatinib therapy (oral dose of 400 mg OD) were monitored for 12 months. The correlation of pre-treatment miR-486-5p levels with Sokal score indicated that patients with a higher expression of miR-486-5p had better prognoses. Patients with higher pre-imatinib miR-486-5p levels also showed a major hematologic response to imatinib in a shorter time and vice versa. To the best of our knowledge, this is the first report of alterations in the miR-486-5p expression in peripheral blood leucocytes of CML patients. Our observations support a tumor suppressor role of miR-486-5p in CML. The downregulation of the miR-486-5p expression may be critically important in the disease progression of CML patients. The upregulation of the miR-486-5p expression in post-imatinib exposure K562 cells and CML patients after 12 months of imatinib treatment suggests an onco-suppressor effector role of miR-486-5p in the BCR-ABL downstream signaling pathway. miR-486-5p can be explored as a novel biomarker for the early detection of CML.
Collapse
Affiliation(s)
- Anupama Ninawe
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Sameer Ahmad Guru
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Prasant Yadav
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Mirza Masroor
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Amit Samadhiya
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Namrata Bhutani
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Naresh Gupta
- Department of Medicine, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Richa Gupta
- Department of Pathology, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi 110002, India
| |
Collapse
|
28
|
Sumi MP, Guru SA, Mir R, Bhat MA, Sahu S, Girish MP, Saxena A. Molecular evaluation of exon 8 cystathionine rs5742905T T>C gene polymorphism and determination of its frequency, distribution pattern, and association with susceptibility to Coronary Artery Disease. In North Indian Population. Cardiovasc Hematol Disord Drug Targets 2021; 21:115-122. [PMID: 33719952 DOI: 10.2174/1871529x21666210315121027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 01/04/2021] [Accepted: 01/18/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The protein coded by cystathionine β synthase (CBS) gene act as a catalyzer, converts homocysteine to cystathionine. Impairment of CBS gene leads to homocystinuria by cystathionine β synthase deficiency which is linked to Coronary Artery Disease. A number of polymorphisms study have been performed in cystathione β synthase gene. In the current study we planned to analyze the influence of CBS T833C gene polymorphism and its association with Coronary Artery Disease development and its progression in the north Indian population. MATERIALS AND METHOD The present study comprises 100 angiographically confirmed CAD patients and 100 age and sex-matched healthy controls. A ≥ 50% luminal stenosis at one major coronary artery was considered for the inclusion criteria of the cases. The investigation of T833C polymorphism in the CBS gene was performed by PCR- RFLP technique. RESULT In result, we found that homozygous mutant (CC ) and heterozygous (TC) genotypes of CBS T833C gene polymorphism, were significantly higher in CAD patients as compared to healthy subjects. We also observed a substantial increased CAD risk exists in dominant, codominant inheritance and allele specific models for the CBS T833C gene polymorphism. We, analyzed the differential distribution with respect to disease severity, but there was no significant association (p=0.96). CONCLUSION In conclusion, this study demonstrates that CBS T833C gene polymorphism plays a key role in developing coronary artery disease and its progression.
Collapse
Affiliation(s)
- Mamta P Sumi
- Department of Biochemistry, Maulana Azad Medical College, University of Delhi. India
| | - Sameer Ahmad Guru
- Department of Biochemistry and Multidisciplinary Research Unit (MRU), MAMC, University of Delhi. India
| | - Rashid Mir
- Prince Fahd Bin Sultan Research chair, Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk . Saudi Arabia
| | - Musadiq A Bhat
- Institute of Pharmacology and Toxicology-Neuropharmacology, University of Zurich Winterthurerstrasse, Zurich. Switzerland
| | - Samantak Sahu
- Department of Physical Medicine and Rehabilitation, All India Institute of Medical Science. India
| | - M P Girish
- iDepartment of Cardiology, GB Pant Hospital, University of Delhi. India
| | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College, University of Delhi. India
| |
Collapse
|
29
|
Amle D, Das J, Chandra L, Gandhi G, Patnayak R, Khurana N, Saxena A. Evaluation of promoter hypermethylation of tumor suppressor gene BRCA1 in epithelial ovarian cancer. J Cancer Res Ther 2021; 18:1578-1582. [DOI: 10.4103/jcrt.jcrt_390_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Ojha V, Verma M, Kumar S, Saxena A. Imaging of the spectrum of abnormal systemic arterial supply to the lungs using dual-source CT. Clin Radiol 2020; 76:235.e1-235.e14. [PMID: 33293026 DOI: 10.1016/j.crad.2020.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Accepted: 11/03/2020] [Indexed: 10/22/2022]
Abstract
Abnormal systemic arterial supply to the lungs can be seen in various congenital and acquired diseases. Identification and characterisation of aberrant vascular supply is essential for further management and treatment. Multidetector computed tomography (CT) with its multiplanar capabilities and volume-rendering techniques provides precise information regarding the anatomy and spatial relationship of arterial vascular channels. The following concise review elucidates the characteristic imaging findings of conditions in which systemic arteries are seen supplying the lung parenchyma on dual-source CT.
Collapse
Affiliation(s)
- V Ojha
- Department of Cardiovascular Radiology & Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, 110029, India
| | - M Verma
- Department of Cardiovascular Radiology & Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, 110029, India
| | - S Kumar
- Department of Cardiovascular Radiology & Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, 110029, India.
| | - A Saxena
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, 110029, India
| |
Collapse
|
31
|
Mohan A, Ansari A, Masroor M, Saxena A, Pandey RM, Upadhyay A, Luthra K, Khilnani GC, Jain D, Kumar R, Guleria R. Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer. Asian Pac J Cancer Prev 2020; 21:3153-3163. [PMID: 33247670 PMCID: PMC8033130 DOI: 10.31557/apjcp.2020.21.11.3153] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2019] [Indexed: 01/09/2023] Open
Abstract
Background: EGFR over-expression plays a key role in the development and progression of lung cancer. However, its status as a prognostic biomarker for survival outcomes is unclear. Objectives: To evaluate the prognostic utility of serum EGFR mRNA expression in Non-Small cell lung cancer (NSCLC) for treatment response and survival. Methods: EGFR mRNA levels were determined in serum using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Based on ROC curve, a cut off value of 16.0-fold increase was selected to categorize patients into low EGFR (≤ 16.0) and high EGFR (> 16.0) groups. Results: A total of 350 subjects were included (78.3% males), with mean (± SD) age of 57.1 (± 11.2) years, and including 247 (70.6%) adenocarcinoma (ADC). Majority (73.1%) had metastatic (stage IV) disease. Patients had higher pre-treatment serum EGFR mRNA levels than controls [median fold-increase (min, max), 16.2 (1.9, 66.7). Serum EGFR mRNA levels significantly reduced in those who achieved objective response and disease control. Significantly longer OS and PFS was observed in subjects having baseline EGFR mRNA expression ≤ 16.0 fold- increase compared to those with > 16.0 fold- increase [median (95% CI) OS: 25.0 (14.9, NR) versus 7.7 (6.3, 8.9) months; HR (95% CI) 2.9 (2.3, 4.0), p< 0.001; and PFS: 9.9 (7.1, 11.5) versus 6.0 (4.1, 7.5) months; HR (95% CI) 1.8 (1.3, 2.4), p< 0.001]. Conclusion: Serum EGFR mRNA expression is a useful parameter for predicting treatment response and survival outcomes in NSCLC.
Collapse
Affiliation(s)
- Anant Mohan
- Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India
| | - Ashraf Ansari
- Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India
| | - Mirza Masroor
- Department of Biochemistry, Maulana Azad Medical College, New Delhi, India
| | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College, New Delhi, India
| | - R M Pandey
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi
| | - Ashish Upadhyay
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi
| | - Kalpana Luthra
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi
| | - G C Khilnani
- Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India
| | - Deepali Jain
- Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
| | - Rakesh Kumar
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Randeep Guleria
- Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
32
|
Guerrero C, Lerendegui-Marco J, Paul M, Tessler M, Heinitz S, Domingo-Pardo C, Cristallo S, Dressler R, Halfon S, Kivel N, Köster U, Maugeri EA, Palchan-Hazan T, Quesada JM, Rochman D, Schumann D, Weissman L, Aberle O, Amaducci S, Andrzejewski J, Audouin L, Bécares V, Bacak M, Balibrea J, Barak A, Barbagallo M, Barros S, Bečvář F, Beinrucker C, Berkovits D, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Buzaglo Y, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Dafna H, Damone A, Diakaki M, Dietz M, Dupont E, Durán I, Eisen Y, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Glodariu T, Gonçalves IF, González-Romero E, Goverdovski A, Griesmayer E, Gunsing F, Harada H, Heftrich T, Heyse J, Hirsh T, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kaizer B, Katabuchi T, Kavrigin P, Ketlerov V, Khryachkov V, Kijel D, Kimura A, Kokkoris M, Kriesel A, Krtička M, Leal-Cidoncha E, Lederer-Woods C, Leeb H, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Manna A, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Mendoza E, Mengoni A, Milazzo PM, Millán-Callado MA, Mingrone F, Mirea M, Montesano S, Musumarra A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Piersanti L, Porras I, Praena J, Rajeev K, Rauscher T, Reifarth R, Rodríguez-González T, Rout PC, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Shor A, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiss C, Wolf C, Woods PJ, Wright T, Žugec P. Neutron Capture on the s-Process Branching Point ^{171}Tm via Time-of-Flight and Activation. Phys Rev Lett 2020; 125:142701. [PMID: 33064503 DOI: 10.1103/physrevlett.125.142701] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 07/02/2020] [Accepted: 07/29/2020] [Indexed: 06/11/2023]
Abstract
The neutron capture cross sections of several unstable nuclides acting as branching points in the s process are crucial for stellar nucleosynthesis studies. The unstable ^{171}Tm (t_{1/2}=1.92 yr) is part of the branching around mass A∼170 but its neutron capture cross section as a function of the neutron energy is not known to date. In this work, following the production for the first time of more than 5 mg of ^{171}Tm at the high-flux reactor Institut Laue-Langevin in France, a sample was produced at the Paul Scherrer Institute in Switzerland. Two complementary experiments were carried out at the neutron time-of-flight facility (n_TOF) at CERN in Switzerland and at the SARAF liquid lithium target facility at Soreq Nuclear Research Center in Israel by time of flight and activation, respectively. The result of the time-of-flight experiment consists of the first ever set of resonance parameters and the corresponding average resonance parameters, allowing us to make an estimation of the Maxwellian-averaged cross sections (MACS) by extrapolation. The activation measurement provides a direct and more precise measurement of the MACS at 30 keV: 384(40) mb, with which the estimation from the n_TOF data agree at the limit of 1 standard deviation. This value is 2.6 times lower than the JEFF-3.3 and ENDF/B-VIII evaluations, 25% lower than that of the Bao et al. compilation, and 1.6 times larger than the value recommended in the KADoNiS (v1) database, based on the only previous experiment. Our result affects the nucleosynthesis at the A∼170 branching, namely, the ^{171}Yb abundance increases in the material lost by asymptotic giant branch stars, providing a better match to the available pre-solar SiC grain measurements compared to the calculations based on the current JEFF-3.3 model-based evaluation.
Collapse
Affiliation(s)
- C Guerrero
- Universidad de Sevilla, Seville, Spain
- Centro Nacional de Aceleradores (CNA) (Universidad de Sevilla-Junta de Andalucía-CSIC), Seville, Spain
| | | | - M Paul
- Hebrew University, Jerusalem, Israel
| | - M Tessler
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - S Heinitz
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - C Domingo-Pardo
- Instituto de Física Corpuscular (CSIC-University of Valencia), Valencia, Spain
| | - S Cristallo
- INAF-Osservatorio Astronomico d'Abruzzo, Teramo, Italy
- INFN Sezione Perugia, Perugia, Italy
| | - R Dressler
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - S Halfon
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - N Kivel
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - U Köster
- Institut Laue-Langevin ILL, Grenoble, France
| | - E A Maugeri
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | | | | | - D Rochman
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - D Schumann
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - L Weissman
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - O Aberle
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Amaducci
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | | | - L Audouin
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - V Bécares
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M Bacak
- Technische Universität Wien, Vienna, Austria
| | - J Balibrea
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Barak
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Barbagallo
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - S Barros
- Instituto Superior Técnico, Lisbon, Portugal
| | - F Bečvář
- Charles University, Prague, Czech Republic
| | | | - D Berkovits
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - E Berthoumieux
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - J Billowes
- University of Manchester, Manchester, United Kingdom
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | - M Brugger
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y Buzaglo
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Caamaño
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - F Calviño
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - M Calviani
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Cano-Ott
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Cardella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Casanovas
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - D M Castelluccio
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - F Cerutti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y H Chen
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - E Chiaveri
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - N Colonna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - G Cortés
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | | | - L Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - H Dafna
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - A Damone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Dipartimento di Fisica, Università degli Studi di Bari, Bari, Italy
| | - M Diakaki
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - M Dietz
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - E Dupont
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - I Durán
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - Y Eisen
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - A Ferrari
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Ferreira
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - V Furman
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - K Göbel
- Goethe University Frankfurt, Seville, Germany
| | - A R García
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Gawlik
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - T Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | | | - E González-Romero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Goverdovski
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | | | - F Gunsing
- Institut Laue-Langevin ILL, Grenoble, France
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - T Heftrich
- Goethe University Frankfurt, Seville, Germany
| | - J Heyse
- Universitat Politècnica de Catalunya, Barcelona, Spain
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - T Hirsh
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - E Jericha
- Technische Universität Wien, Vienna, Austria
| | - F Käppeler
- Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
| | - Y Kadi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Kaizer
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - P Kavrigin
- Technische Universität Wien, Vienna, Austria
| | - V Ketlerov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - V Khryachkov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - D Kijel
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - M Kokkoris
- National Technical University of Athens, Athens, Greece
| | - A Kriesel
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Krtička
- Charles University, Prague, Czech Republic
| | - E Leal-Cidoncha
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - C Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - H Leeb
- Technische Universität Wien, Vienna, Austria
| | - S Lo Meo
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - R Losito
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Macina
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Manna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | | | - T Martínez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C Massimi
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - P Mastinu
- Istituto Nazionale di Fisica Nucleare, Sezione di Legnaro, Italy
| | - M Mastromarco
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - F Matteucci
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
- Dipartimento di Astronomia, Università di Trieste, Trieste, Italy
| | - E Mendoza
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Mengoni
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
| | - P M Milazzo
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
| | - M A Millán-Callado
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - F Mingrone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - M Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | - S Montesano
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Musumarra
- INFN Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Catania, Italy
| | - R Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - A Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | - N Patronis
- University of Ioannina, Ioannina, Greece
| | - A Pavlik
- University of Vienna, Faculty of Physics, Vienna, Austria
| | | | - L Piersanti
- INAF-Osservatorio Astronomico d'Abruzzo, Teramo, Italy
| | - I Porras
- University of Granada, Granada, Spain
| | - J Praena
- Universidad de Sevilla, Seville, Spain
- University of Granada, Granada, Spain
| | - K Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T Rauscher
- Centre for Astrophysics Research, University of Hertfordshire, Hatfield, United Kingdom
- Department of Physics, University of Basel, Basel, Switzerland
| | - R Reifarth
- Goethe University Frankfurt, Seville, Germany
| | - T Rodríguez-González
- Universidad de Sevilla, Seville, Spain
- Centro Nacional de Aceleradores (CNA) (Universidad de Sevilla-Junta de Andalucía-CSIC), Seville, Spain
| | - P C Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - C Rubbia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J A Ryan
- University of Manchester, Manchester, United Kingdom
| | - M Sabaté-Gilarte
- Universidad de Sevilla, Seville, Spain
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - S Schmidt
- Goethe University Frankfurt, Seville, Germany
| | - A Shor
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - P Sedyshev
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - A G Smith
- University of Manchester, Manchester, United Kingdom
| | | | - G Tagliente
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - J L Tain
- Instituto de Física Corpuscular (CSIC-University of Valencia), Valencia, Spain
| | | | - L Tassan-Got
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - A Tsinganis
- National Technical University of Athens, Athens, Greece
| | - S Valenta
- Charles University, Prague, Czech Republic
| | - G Vannini
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - V Variale
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - P Vaz
- Instituto Superior Técnico, Lisbon, Portugal
| | - A Ventura
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - V Vlachoudis
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Vlastou
- National Technical University of Athens, Athens, Greece
| | - A Wallner
- Australian National University, Canberra, Australia
| | - S Warren
- University of Manchester, Manchester, United Kingdom
| | - M Weigand
- Goethe University Frankfurt, Seville, Germany
| | - C Weiss
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Technische Universität Wien, Vienna, Austria
| | - C Wolf
- Goethe University Frankfurt, Seville, Germany
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, Manchester, United Kingdom
| | - P Žugec
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
33
|
Manna A, Aberle O, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Babiano VS, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calvi F, Cano-Ott D, Casanovas A, Cerutti F, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Coséntino L, Cristallo S, Damone LA, Davies PJ, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Goncalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Jiri U, Junghans A, Kadi Y, Käppeler F, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Krtiička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Lonsdale SJ, Macina D, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Michalopoulou V, Milazzo PM, Millán-Callado MA, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, Quesada J, Ramos D, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith A, Sosnin N, Sprung P, Stamatopoulos A, Tagliente G, Tain JL, Tarifeno-Saldivia AE, Tassan-Got L, Thomas B, Torres-Sánchez P, Tsinganis A, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Setup for the measurement of the 235U(n, f) cross section relative to n-p scattering up to 1 GeV. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The neutron induced fission of 235U is extensively used as a reference for neutron fluence measurements in various applications, ranging from the investigation of the biological effectiveness of high energy neutrons, to the measurement of high energy neutron cross sections of relevance for accelerator driven nuclear systems. Despite its widespread use, no data exist on neutron induced fission of 235U above 200 MeV. The neutron facility n_TOF offers the possibility to improve the situation. The measurement of 235U(n,f) relative to the differential n-p scattering cross-section, was carried out in September 2018 with the aim of providing accurate and precise cross section data in the energy range from 10 MeV up to 1 GeV. In such measurements, Recoil Proton Telescopes (RPTs) are used to measure the neutron flux while the fission events are detected and counted with dedicated detectors. In this paper the measurement campaign and the experimental set-up are illustrated.
Collapse
|
34
|
Terranova N, Aberle O, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Cano-Ott D, Casanovas A, Cerutti F, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Davies PJ, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Jiri U, Junghans A, Kadi Y, Käppeler F, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Michalopoulou V, Milazzo PM, Millán-Callado MA, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, Quesada JM, Doval DR, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith AG, Sosnin N, Sprung P, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia AE, Tassan-Got L, Thomas B, Torres-Sánchez P, Tsinganis A, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Monte Carlo simulations and n-p differential scattering data measured with Proton Recoil Telescopes. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The neutron-induced fission cross section of 235U, a standard at thermal energy and between 0.15 MeV and 200 MeV, plays a crucial role in nuclear technology applications. The long-standing need of improving cross section data above 20 MeV and the lack of experimental data above 200 MeV motivated a new experimental campaign at the n_TOF facility at CERN. The measurement has been performed in 2018 at the experimental area 1 (EAR1), located at 185 m from the neutron-producing target (the experiment is presented by A. Manna et al. in a contribution to this conference). The 235U(n,f) cross section from 20 MeV up to about 1 GeV has been measured relative to the 1H(n,n)1H reaction, which is considered the primary reference in this energy region. The neutron flux impinging on the 235U sample (a key quantity for determining the fission events) has been obtained by detecting recoil protons originating from n-p scattering in a C2H4 sample. Two Proton Recoil Telescopes (PRT), consisting of several layers of solid-state detectors and fast plastic scintillators, have been located at proton scattering angles of 25.07° and 20.32°, out of the neutron beam. The PRTs exploit the ΔE-E technique for particle identification, a basic requirement for the rejection of charged particles from neutron-induced reactions in carbon. Extensive Monte Carlo simulations were performed to characterize proton transport through the different slabs of silicon and scintillation detectors, to optimize the experimental set-up and to deduce the efficiency of the whole PRT detector. In this work we compare measured data collected with the PRTs with a full Monte Carlo simulation based on the Geant-4 toolkit.
Collapse
|
35
|
Pyngrope A, Khardewsaw A, Sharma Y, Maibam D, Saxena A, Sahoo BK. STUDY OF INDOOR RADON, THORON AND THEIR PROGENY IN SOUTH WEST KHASI HILLS DISTRICT OF MEGHALAYA, INDIA. Radiat Prot Dosimetry 2020; 189:347-353. [PMID: 32342102 DOI: 10.1093/rpd/ncaa048] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 03/07/2020] [Accepted: 03/10/2020] [Indexed: 06/11/2023]
Abstract
A survey of indoor radon/thoron and their progeny concentrations was carried out in dwellings in the South West Khasi Hills district of Meghalaya, India. The survey was carried out using solid-state nuclear track detectors based on single-entry pinhole dosimeter and direct radon/thoron progeny sensors. The results are subjected to statistical analysis and discussed in the manuscript. The mean value of annual effective dose of the study region is estimated at 1.8 mSv.y -1. Seasonal variability and role of different indoor parameters are also discussed.
Collapse
Affiliation(s)
- A Pyngrope
- Department of Physics, North-Eastern Hill University, Shillong 793022, India
| | - A Khardewsaw
- Department of Physics, North-Eastern Hill University, Shillong 793022, India
| | - Y Sharma
- Department of Physics, Don Bosco College, Tura 794001, India
| | - D Maibam
- Don Bosco College of Teacher Education, Tura 794001, India
| | - A Saxena
- Department of Physics, North-Eastern Hill University, Shillong 793022, India
| | - B K Sahoo
- Radiological Physics and Advisory Division, BARC, Mumbai 400085, India
| |
Collapse
|
36
|
Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 2020; 31:861-872. [PMID: 32272210 DOI: 10.1016/j.annonc.2020.03.299] [Citation(s) in RCA: 74] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 03/15/2020] [Indexed: 01/05/2023] Open
Abstract
A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the Taiwan Oncology Society (TOS). The purpose of the meeting was to focus on what we have learnt from both microsatellite instability (MSI)/deficient mismatch repair (dMMR) biomarkers in predicting the efficacy of anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy, and the neurotrophic tyrosine receptor kinase (NTRK) gene fusions in predicting the efficacy of inhibitors of the tropomyosin receptor kinase (TRK) proteins across a range of solid tumour types. The recent regulatory approvals of the anti-PD-1 antibody pembrolizumab and the TRK inhibitors larotrectinib and entrectinib, based on specific tumour biomarkers rather than specific tumour type, have heralded a paradigm shift in cancer treatment approaches. The purpose of the meeting was to develop international expert consensus recommendations on the use of such tumour-agnostic treatments in patients with solid tumours. The aim was to generate a reference document for clinical practice, for pharmaceutical companies in the design of clinical trials, for ethics committees in the approval of clinical trial protocols and for regulatory authorities in relation to drug approvals, with a particular emphasis on diagnostic testing and patient selection.
Collapse
Affiliation(s)
- T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
| | - G Pentheroudakis
- Department of Medical Oncology, University of Ioannina, Ioannina, Greece
| | - S Mishima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - M J Overman
- Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - K-H Yeh
- Department of Medical Oncology, National Taiwan University Cancer Center and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
| | - E Baba
- Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Naito
- Department of Experimental Therapeutics/Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - F Calvo
- Department of Clinical Pharmacology, University of Paris and Institute Gustave Roussy, Villejuif, France
| | - A Saxena
- Department of Medicine, Division of Hematology & Medical Oncology, Thoracic Oncology Service, Weill Cornell Medicine, New York, USA
| | - L-T Chen
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - M Takeda
- Department of Medical Oncology, Kindai University, Osaka, Japan
| | - A Cervantes
- CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
| | - H Taniguchi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - K Yoshida
- Department of Surgical Oncology, Gifu University, Graduate School of Medicine, Gifu, Japan
| | - Y Kodera
- Department of Gastrointestinal Surgery, Nagoya University, Nagoya, Japan
| | - Y Kitagawa
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - J Tabernero
- Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain
| | - H Burris
- The Sarah Cannon Research Institute, Nashville, USA
| | | |
Collapse
|
37
|
Furie R, Rovin BH, Houssiau F, Amoura Z, Santiago M, Contreras G, Malvar A, Mok CC, Saxena A, Yu X, Teng YKO, Barnett C, Burriss S, Green Y, Ji B, Kleoudis C, Roth D. OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3881] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), affects nearly 70% of patients (pts) in high-risk groups. To preserve renal function, LN requires fast and effective treatment. Despite medical advances, progression rates at 15 years to end-stage renal disease (ESRD) remain >40% for pts with diffuse proliferative LN. Belimumab (BEL), approved in pts aged ≥5 years with active SLE, improved renal parameters in pts with baseline renal involvement in apost hocanalysis of Phase 3 trials data.Objectives:To assess efficacy and safety of intravenous (IV) BEL vs placebo (PBO), plus standard therapy (ST), in pts with active LN.Methods:BLISS-LN is a Phase 3, randomised, double-blind, PBO-controlled, 104-week study (GSK Study BEL114054,NCT01639339). Adults with SLE and biopsy-proven LN (class III, IV, and/or V) were randomised (1:1) to monthly BEL 10 mg/kg IV or PBO, plus ST. Primary endpoint: Primary Efficacy Renal Response (PERR); defined as urine protein creatinine ratio [uPCR] ≤0.7; estimated glomerular filtration rate [eGFR] within 20% of the pre-flare value or ≥60 ml/min/1.73m2; no rescue therapy) at Week (Wk) 104. Key secondary endpoints: Complete Renal Response (CRR; defined as uPCR <0.5; eGFR within 10% of the pre-flare value or ≥90 ml/min/1.73m2; no rescue therapy) at Wk 104; PERR at Wk 52; time to renal-related event (defined as ESRD/doubling of serum creatinine/renal worsening/renal disease-related treatment failure) or death. Other endpoints: time to PERR/CRR sustained through Wk 104; SLEDAI-S2K score <4 points at Wk 104; safety.Results:Overall, 448 pts were randomised (efficacy: 223/group; safety: 224/group). Significantly more BEL (43%) than PBO (32.3%) pts achieved PERR at Wk 104 (OR 1.55, 95% CI 1.04, 2.32; p=0.0311). More BEL than PBO pts achieved key secondary and other efficacy endpoints (Table).Overall, 214 (95.5%) BEL and 211 (94.2%) PBO pts had ≥1 adverse event (AE); 58 (25.9%) BEL and 67 (29.9%) PBO pts had ≥1 serious AE; 29 (12.9%) pts in each group had ≥1 AE resulting in study treatment discontinuation; 4 (1.8%) BEL and 3 (1.3%) PBO pts developed on-treatment fatal AEs.Conclusion:In the largest LN study to date, data from BLISS-LN demonstrate that BEL plus ST significantly improves LN renal responses compared with ST alone with a favourable safety profile.Study funding: GSK.Table.Endpoint, n (%)PBO(n=223)BEL(n=223)OR/HR (95% CI) vs PBOp-valueCRR at Wk 104*44 (19.7)67 (30.0)OR 1.74(1.11, 2.74)0.0167PERR at Wk 52*79 (35.4)104 (46.6)OR 1.59(1.06, 2.38)0.0245Time to PERR throughWk 104†72 (32.3)96 (43.0)HR 1.46(1.07, 1.98)0.0157Time to CRR throughWk 104†44 (19.7)67 (30.0)HR 1.58(1.08, 2.31)0.0189Time to renal-related event or death†63 (28.3)35 (15.7)HR 0.51(0.34, 0.77)0.0014SLEDAI-S2K score <4 points at Wk 104*41 (18.4)62 (27.8)OR 1.76(1.11, 2.78)0.0164*PBO and BEL columns represent the n (%) responders†Data presented as n (cumulative incidence)Disclosure of Interests:Richard Furie Grant/research support from: GSK, Consultant of: GSK, Brad H Rovin Grant/research support from: GSK, Consultant of: GSK, Frederic Houssiau Grant/research support from: UCB, Consultant of: GSK, Zahir Amoura Grant/research support from: GSK, Roche, Consultant of: GSK, Astra Zeneca, Amgen, Mittermayer Santiago: None declared, Gabriel Contreras Grant/research support from: Genentech, Merck, Consultant of: Genentech, Merck, Ana Malvar Consultant of: GSK and Roche, chi chiu mok: None declared, Amit Saxena Consultant of: GSK, AZ, BMS, Xueqing Yu: None declared, Y.K. Onno Teng Grant/research support from: GSK, Consultant of: GSK, Aurinia Pharmaceuticals, Novartis, Carly Barnett Shareholder of: GSK, Employee of: GSK, Susan Burriss Shareholder of: GSK, Employee of: GSK, Yulia Green Shareholder of: GSK, Employee of: GSK, Beulah Ji Shareholder of: GSK, Employee of: GSK, Christi Kleoudis Shareholder of: GSK, Consultant of: GSK, Employee of: Parexel, David Roth Shareholder of: GSK, Employee of: GSK
Collapse
|
38
|
Sumi MP, Guru SA, Sahu S, Khan B, Mp G, Saxena A. “Role of HFE gene in coronary artery disease” – A study from India. Clinical Epidemiology and Global Health 2020. [DOI: 10.1016/j.cegh.2019.10.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
39
|
Biswas BK, Guru SA, Sumi MP, Jamatia E, Gupta RK, Lali P, Konar BC, Saxena A, Mir R. Natural Killer Cells Expanded and Preactivated Exhibit Enhanced Antitumor Activity against Different Tumor Cells in Vitro. Asian Pac J Cancer Prev 2020; 21:1595-1605. [PMID: 32592353 PMCID: PMC7568895 DOI: 10.31557/apjcp.2020.21.6.1595] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Indexed: 11/25/2022] Open
Abstract
One of the emerging treatment strategies for cancer particularly for haematological malignancies is natural killer (NK) cell therapy. However, the availability of a best approach to maximize NK cell anticancer potential is still awaited. It is well established that cytokine-induced memory-like NK cells have the potential to differentiate after a short period of preactivation with interleukins-IL-12, IL-15, and IL-18 and exhibit increased responses to cytokine or activating receptor restimulation for weeks to months after preactivation. We demonstrated that NK cells differentiated from CD34+ cells isolated from cord blood show increased antitumor potential in vitro against different cancer cells. Using flow cytometry, we found that NK cells were able to induce apoptosis in cancer cells in vitro. We further analysed surviving gene expression by quantitative real time PCR and reported that NK cells cause down regulation of survivin gene expression in tumor cells. Therefore, NK cell therapy represents a promising immunotherapy for cancers like AML and other haematological malignancies. It concluded that NK cells can be differentiated from CD34+ cells isolated from cord blood ,are able to induce apoptosis and induce increased antitumor potential in vitro against different cancer cells besides cause downregulation of survivin gene expression in tumor cells. Therefore, NK cell therapy represents a promising immunotherapy for different cancer types and haematological malignancies. Furthers studies are necessary to confirm our findings.
Collapse
Affiliation(s)
- Biplob Kumar Biswas
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Sameer Ahmad Guru
- Multidisciplinary Research Unit (MRU), Maulana Azad Medical College and Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India
| | - Mamta Pervin Sumi
- Department of Gastroinstestinal Surgery G B Pant Postgraduate Institute of Medical Education and Research (GIPMER), New Delhi, India
| | - Elvia Jamatia
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Rohit Kumar Gupta
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Pramod Lali
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Bidhan Chandra Konar
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College (MAMC) and Associated Hospitals, New Delhi, India
| | - Rashid Mir
- Department of Medical Lab Technology, Faculty of Applied Medical Sciences, Prince Fahd Bin Sultan Research chair, University of Tabuk, Saudi Arabia
| |
Collapse
|
40
|
Guru SA, Sumi MP, Mir R, Waza AA, Bhat MA, Zuberi M, Lali P, Saxena A. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum Cell 2020; 33:1099-1111. [PMID: 32430672 DOI: 10.1007/s13577-020-00370-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Accepted: 04/24/2020] [Indexed: 02/08/2023]
Abstract
Escalated PD-L1 expression has been identified during malignant transformation in a number of cancer types and helps cancer cells escape an effective anti-tumor immune response. The mechanisms underlying escalated production of PD-L1 in many cancers, however, are still far from clear. We studied PD-L1, STAT3 and STAT5 mRNA expression using qRT-PCR in 72 BCR/ABL1 negative myeloproliferative neoplasm (MPN) patients (39 polycythemia vera and 33 essential thrombocythemia). Furthermore, phosphorylation status of STAT3 and STAT5 was studied using immunoblotting in the same patients. All MPN patients were first screened for JAK2 (V617F) mutation by tetra-primer ARMS-PCR, followed by quantification of JAK2 (V617F) mutation burden in all V617F positive MPN patients by ASO-PCR. Patients were screened for BCR/ABL1 fusion gene transcripts to rule out Ph positive status. Our findings showed that mRNA levels of PD-L1 and STAT3 were significantly higher in JAK2 (V617F) MPN patients, while as STAT5 was insignificantly upregulated. STAT3 and STAT5 phosphorylation was seen to be higher in JAK2 (V617F) MPN patients compared to the JAK2 (WT) patients. Upregulation of PD-L1, STAT3 and STAT5 was significantly associated with JAK2 (V617F) percentage in MPN patients. PD-L1, STAT3 and STAT5 expression significantly and positively correlated with JAK2 (V617F) allele burden. In addition, significant coexpression of PD-L1 with STAT3 and STAT5 was observed in MPN patients. In summary, JAK2 (V617F) mutation is accompanied by increased PD-L1 expression and this PD-L1 over expression is mediated by JAK2 (V617F) mainly through STAT3, while as STAT5 may play a minor role.
Collapse
Affiliation(s)
- Sameer Ahamd Guru
- Multidisciplinary Research Unit (MRU), Maulana Azad Medical College and Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India
| | - Mamta P Sumi
- Department of Gastroinstestinal Surgery, Govind Balab Pant Postgraduate Institute of Medical Education and Research (GIPMER), New Delhi, India
| | - Rashid Mir
- University of Tabuk, Tabuk, Saudi Arabia
| | - Ajaz Ahmad Waza
- Centre of Research for Development (CORD), University of Kashmir, Srinagar, India
| | - Musadiq Ahmad Bhat
- Institute of Pharmacology and Toxicology-Neuropharmacology, University of Zurich Winterthurerstrasse, Zurich, Switzerland
| | - Mariyam Zuberi
- University of Illinois At Chicago College of Medicine, Chicago, USA
| | - Promod Lali
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India
| | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India.
| |
Collapse
|
41
|
Bhadwal AS, Mottram NJ, Saxena A, Sage IC, Brown CV. Electrically controlled topological micro cargo transportation. Soft Matter 2020; 16:2961-2970. [PMID: 32119011 DOI: 10.1039/c9sm01956a] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
We demonstrate electrically controlled linear translation and precision positioning of a colloidal particle in a soft matter device. The basis of transportation is the time dependent electric field reconfiguration and manipulation of a topological line defect between two distinct hybrid aligned nematic liquid crystal domains having opposing tilt orientations. Deliberately tuning an applied voltage relative to a low threshold value (5.7 V at 1 kHz) permits defect trapping of the colloidal particle and allows subsequent control over the particle's velocity and bidirectional linear movement over millimeter distances, without the need for externally imposed flow nor for lateral confining walls.
Collapse
Affiliation(s)
- A S Bhadwal
- SOFT Group, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.
| | | | | | | | | |
Collapse
|
42
|
Massimi C, Aberle O, Andrzejewski J, Audouin L, Bacak M, Balibrea J, Barbagallo M, Bečvář F, Berthoumieux E, Billowes J, Bosnar D, Brown A, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Clai G, Colonna N, Console Camprini P, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Diakaki M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Gilardoni S, Glodariu T, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Guglielmelli A, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kalamara A, Kavrigin P, Kimura A, Kivel N, Knapova I, Kokkoris M, Krtička M, Kurtulgil D, Leal-Cidoncha E, Lederer C, Leeb H, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Marganiec J, Martínez T, Masi A, Mastinu P, Mastromarco M, Maugeri EA, Mazzone A, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Mucciola R, Musumarra A, Negret A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Radeck D, Rauscher T, Reifarth R, Rocchi F, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sedyshev P, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weiss C, Woods PJ, Wright T, Žugec P. Measurement and analysis of 155,157Gd(n, γ) from thermal energy to 1 keV. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We have measured the capture cross section of the 155Gd and 157Gd isotopes between 0.025 eV and 1 keV. The capture events were recorded by an array of 4 C6D6 detectors, and the capture yield was deduced exploiting the total energy detection system in combination with the Pulse Height Weighting Techniques. Because of the large cross section around thermal neutron energy, 4 metallic samples of different thickness were used to prevent problems related to self-shielding. The samples were isotopically enriched, with a cross contamination of the other isotope of less than 1.14%. The capture yield was analyzed with an R-Matrix code to describe the cross section in terms of resonance parameters. Near thermal energies, the results are significantly different from evaluations and from previous time-of-flight experiments. The data from the present measurement at n_TOF are publicly available in the experimental nuclear reaction database EXFOR.
Collapse
|
43
|
Barbagallo M, Aberle O, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Bennett S, Berthoumieux E, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Cano-Ott D, Casanovas A, Cerutti F, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Davies PJ, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Jiri U, Junghans A, Kadi Y, Käppeler F, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Michalopoulou V, Milazzo PM, Millán-Callado MA, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, Quesada JM, Ramos Doval D, Reifarth R, Rochman D, Rubbia C, Sabaté- Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith AG, Sosnin N, Sprung P, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia AE, Tassan-Got L, Thomas B, Torres-Sánchez P, Tsinganis A, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Measurement of the energy-differential cross-section of the 12C(n,p) 12B and 12C(n,d) 11B reactions at the n_TOF facility at CERN. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Although the 12C(n,p)12B and 12C(n,d)11B reactions are of interest in several fields of basic and applied Nuclear Physics the present knowledge of these two cross-sections is far from being accurate and reliable, with both evaluations and data showing sizable discrepancies. As part of the challenging n_TOF program on (n,cp) nuclear reactions study, the energy differential cross-sections of the 12C(n,p)12B and 12C(n,d)11 B reactions have been measured at CERN from the reaction thresholds up to 30 MeV neutron energy. Both measurements have been recently performed at the long flight-path (185 m) experimental area of the n_TOF facility at CERN using a pure (99.95%) rigid graphite target and two silicon telescopes. In this paper an overview of the experiment is presented together with a few preliminary results.
Collapse
|
44
|
Bacak M, Aïche M, Bélier G, Berthoumieux E, Diakaki M, Dupont E, Gunsing F, Heyse J, Kopecky S, Krtička M, Laurent B, Leeb H, Mathieu L, Schillebeeckx P, Serot O, Taieb J, Valenta S, Vlachoudis V, Aberle O, Andrzejewski J, Audouin L, Balibrea J, Barbagallo M, Bečvář F, Billowes J, Bosnar D, Brown A, Caamaño M, Calviño F, Calviani, Cano-Ott D, Cardella R, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Domingo-Pardo C, Dressler R, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Gilardoni S, Glodariu T, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Harada H, Heinitz S, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kalamara A, Kavrigin P, Kimura A, Kivel N, Knapova I, Kokkoris M, Kurtulgil D, Leal-Cidoncha E, Lederer C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Marganiec J, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Maugeri EA, Mazzone A, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Radeck D, Rauscher T, Reifarth R, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schumann D, Sedyshev P, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Vannini G, Variale V, Vaz P, Ventura A, Vlastou R, Wallner A, Warren S, Weiss C, Woods PJ, Wright T, Žugec P. Preliminary results on the 233U α-ratio measurement at n_TOF. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
233U is the fissile nuclei in the Th-U fuel cycle with a particularily small neutron capture cross setion which is on average about one order of magnitude lower than its fission cross section. Hence, the measurement of the 233U(n, γ) cross section relies on a method to accurately distinguish between capture and fission γ-rays. A measurement of the 233U α-ratio has been performed at the n_TOF facility at CERN using a so-called fission tagging setup, coupling n_TOF 's Total Absorption Calorimeter with a novel fission chamber to tag the fission γ-rays. The experimental setup is described and essential parts of the analysis are discussed. Finally, a preliminary 233U α-ratio is presented.
Collapse
|
45
|
Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A. The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients. Microrna 2020; 9:49-57. [PMID: 30799804 DOI: 10.2174/2211536608666190225111234] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 11/09/2018] [Accepted: 02/13/2019] [Indexed: 06/09/2023]
Abstract
BACKGROUND Epithelial ovarian cancer continues to be a deleterious threat to women as it is asymptomatic and is typically detected in advanced stages. Cogent non-invasive biomarkers are therefore needed which are effective in apprehending the disease in early stages. Recently, miRNA deregulation has shown a promising magnitude in ovarian cancer tumorigenesis. miRNA-145(miR- 145) is beginning to be understood for its possible role in cancer development and progression. In this study, we identified the clinicopathological hallmarks altered owing to the downexpression of serum miR-145 in EOC. METHODS 70 serum samples from histopathologically confirmed EOC patients and 70 controls were collected. Total RNA from serum was isolated by Trizol method, polyadenylated and reverse transcribed into cDNA. Expression level of miR-145 was detected by miRNA qRT-PCR using RNU6B snRNA as reference. RESULTS The alliance of miR-145 profiling amongst patients and controls established itself to be conspicuous with a significant p-value (p<0.0001). A positive conglomeration (p=0.04) of miR-145 profiling was manifested with histopathological grade. Receiver Operating Characteristic (ROC) curve highlights the diagnostic potential and makes it imminent with a robust Area Under the curve (AUC). A positive correlation with the ROC curve was also noted for histological grade, FIGO stage, distant metastasis, lymph node status and survival. CONCLUSION Our results propose that miR-145 down-regulation might be a possible touchstone for disease progression and be identified as a diagnostic marker and predict disease outcome in EOC patients.
Collapse
Affiliation(s)
- Mariyam Zuberi
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Rashid Mir
- Prince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia
| | - Imran Khan
- Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Columbia, SC, United States
| | - Jamsheed Javid
- Prince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia
| | - Sameer Ahmad Guru
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Musadiq Bhat
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Mamta Pervin Sumi
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Imtiyaz Ahmad
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Mirza Masroor
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | - Prasant Yadav
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| | | | - Alpana Saxena
- Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India
| |
Collapse
|
46
|
Chiaveri E, Aberle O, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Bosnar D, Brown A, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Cano-Ott D, Casanovas A, Cerutti F, Colonna N, Cortés G, Cortés-Giraldo M, Cosentino L, Cristallo S, Damone L, Davies P, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins D, Jericha E, Jiri U, Junghans A, Kadi Y, Käppeler F, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Michalopoulou V, Milazzo P, Millán-Callado M, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, Quesada J, Ramos Doval D, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sekhar A, Smith A, Sosnin N, Sprung P, Stamatopoulos A, Tagliente G, Tain J, Tarifeño-Saldivia A, Tassan-Got L, Thomas B, Torres-Sánchez P, Tsinganis A, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods P, Wright T, Žugec P. Status and perspectives of the neutron time-of-flight facility n_TOF at CERN. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023917001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Since the start of its operation in 2001, based on an idea of Prof. Carlo Rubbia [1], the neutron time of-flight facility of CERN, n_TOF, has become one of the most forefront neutron facilities in the world for wide-energy spectrum neutron cross section measurements. Thanks to the combination of excellent neutron energy resolution and high instantaneous neutron flux available in the two experimental areas, the second of which has been constructed in 2014, n_TOF is providing a wealth of new data on neutron-induced reactions of interest for nuclear astrophysics, advanced nuclear technologies and medical applications. The unique features of the facility will continue to be exploited in the future, to perform challenging new measurements addressing the still open issues and long-standing quests in the field of neutron physics. In this document the main characteristics of the n_TOF facility and their relevance for neutron studies in the different areas of research will be outlined, addressing the possible future contribution of n_TOF in the fields of nuclear astrophysics, nuclear technologies and medical applications. In addition, the future perspectives of the facility will be described including the upgrade of the spallation target, the setup of an imaging installation and the construction of a new irradiation area.
Collapse
|
47
|
Oprea A, Gunsing F, Schillebeeckx P, Aberle O, Bacak M, Berthoumieux E, Cano-Ott D, Diakaki M, Dupont E, Geslot B, Glodariu T, Heyse J, Mendoza E, Negret A, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Bécares V, Babiano-Suarez V, Barbagallo M, Becčvář F, Bellia G, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Caballero-Ontanaya L, Calviño F, Calviani M, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Dietz M, Domingo-Pardo C, Dressler R, Durán I, Eleme Z, Femández-Domínguez B, Ferrari A, Finocchiaro P, Furman V, Göbel K, Garg R, Gawlik A, Gilardoni S, Goncalves IF, González-Romero E, Guerrero C, Harada H, Heinitz S, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kimura A, Kivel N, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Nolte R, Ogállar F, Patronis N, Pavlik A, Perkowski J, Persanti L, Porras I, Praena J, Quesada JM, Radeck D, Ramos-Doval D, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schumann D, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Talip T, Tarifeño-Saldivia A, Tassan-Got L, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright T, Žugec P. Neutron capture cross section measurements of 241Am at the n_TOF facility. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Neutron capture on 241Am plays an important role in the nuclear energy production and also provides valuable information for the improvement of nuclear models and the statistical interpretation of the nuclear properties. A new experiment to measure the 241Am(n, γ) cross section in the thermal region and the first few resonances below 10 eV has been carried out at EAR2 of the n_TOF facility at CERN. Three neutron-insensitive C6D6 detectors have been used to measure the neutron-capture gamma cascade as a function of the neutron time of flight, and then deduce the neutron capture yield. Preliminary results will be presented and compared with previously obtained results at the same facility in EAR1. In EAR1 the gamma-ray background at thermal energies was about 90% of the signal while in EAR2 is up to a 25 factor much more favorable signal to noise ratio. We also extended the low energy limit down to subthermal energies. This measurement will allow a comparison with neutron capture measurements conducted at reactors and using a different experimental technique.
Collapse
|
48
|
Stamatopoulos A, Tsinganis A, Diakaki M, Colonna N, Kokkoris M, Vlastou R, Kalamara A, Schillebeeckx P, Tassan-Got L, Žugec P, Sabaté-Gilarte M, Patronis N, Eleme Z, Heyse J, Aberle O, Andrzejewski J, Audouin L, Bacak M, Balibrea J, Barbagallo M, Bečvář F, Berthoumieux E, Billowes J, Bosnar D, Brown A, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Domingo-Pardo C, Dressler R, Dupont E, Durán, Femandez-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Gilardoni S, Glodariu† T, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heinitz S, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kavrigin P, Kimura A, Kivel N, Knapova I, Krtička M, Kurtulgil D, Leal-Cidoncha E, Lederer C, Leeb H, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Marganiec J, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Maugeri EA, Mazzone A, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Oprea A, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Radeck D, Rauscher T, Reifarth R, Rubbia C, Ryan JA, Saxena A, Schumann D, Sedyshev P, Smith AG, Sosnin NV, Tagliente G, Tain JL, Tarifeño-Saldivia A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Wallner A, Warren S, Weiss C, Woods PJ, Wright T. Study of the neutron-induced fission cross section of 237Np at CERN's n_TOF facility over a wide energy range. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023905006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Neutron-induced fission cross sections of isotopes involved in the nuclear fuel cycle are vital for the design and safe operation of advanced nuclear systems. Such experimental data can also provide additional constraints for the adjustment of nuclear model parameters used in the evaluation process, resulting in the further development of fission models. In the present work, the 237Np(n,f) cross section was studied at the EAR2 vertical beam-line at CERN's n_TOF facility, over a wide range of neutron energies, from meV to MeV, using the time-of-flight technique and a set-up based on Micromegas detectors, in an attempt to provide accurate experimental data. Preliminary results in the 200 keV – 14 MeV neutron energy range as well as the experimental procedure, including a description of the facility and the data handling and analysis, will be presented.
Collapse
|
49
|
Mendoza E, Alcayne V, Cano-Ott D, Kimura A, Skarbeli AV, Aberle O, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bécares V, Bečvář F, Bellia G, Berthoumieux E, Billowes J, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Glodariu T, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Kadi Y, Käppeler F, Kivel N, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Matteucci F, Maugeri E, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Piersanti L, Porras I, Praena J, Quesada JM, Radeck D, Doval DR, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Smith AG, Sosnin N, Stamatopoulos A, Tagliente G, Tain JL, Talip Z, Tarifeño-Saldivia AE, Tassan-Got L, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Study of photon strength functions of 241Pu and 245Cm from neutron capture measurements. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We have measured theγ-rays following neutron capture on240Pu and244Cm at the n_TOF facility at CERN with the Total Absorption Calorimeter (TAC) and with C6D6 organic scintillators. The TAC is made of 40 BaF2 crystals operating in coincidence and covering almost the entire solid angle. This allows to obtain information concerning the energy spectra and the multiplicity of the measured captureγ-ray cascades. Additional information is also obtained from the C6D6 detectors. We have analyzed the measured data in order to draw conclusions about the Photon Strength Functions (PSFs) of241Pu and245Cm below their neutron separation energies. The analysis has been performed by fitting the PSFs to the experimental results, using the differential evolution method, in order to find neutron capture cascades capable of reproducing at the same time a great variety of deposited energy spectra.
Collapse
|
50
|
Amaducci S, Aberle O, Andrzejewski J, Audouin L, Bacak M, Balibrea J, Barbagallo M, Bečvář F, Berthoumieux E, Billowes J, Bosnar D, Brown A, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Girardo MA, Cosentino L, Damone LA, Diakaki M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Gilardoni S, Glodariu T, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kalamara A, Kavrigin P, Kimura A, Kivel N, Knapova I, Kokkoris M, Krtička M, Kurtulgil D, Leal-Cidoncha E, Lederer C, Leeb H, Lerendegui-Marco J, Lo Meo S, Lonsdale SJ, Macina D, Manna A, Marganiec J, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Maugeri EA, Mazzone A, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Radeck D, Rauscher T, Reifarth R, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Sedyshev P, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weiss C, Woods PJ, Wright T, Žugec P. Accurate measurement of the standard 235U(n,f) cross section from thermal to 170 keV neutron energy. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023908002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
An accurate measurement of the 235U(n,f) cross section from thermal to 170 keV of neutron energy has recently been performed at n_TOF facility at CERN using 6Li(n,t)4He and 10B(n,α)7Li as references. This measurement has been carried out in order to investigate a possible overestimation of the 235U fission cross section evaluation provided by most recent libraries between 10 and 30 keV. A custom experimental apparatus based on in-beam silicon detectors has been used, and a Monte Carlo simulation in GEANT4 has been employed to characterize the setup and calculate detectors efficiency. The results evidenced the presence of an overestimation in the interval between 9 and 18 keV and the new data may be used to decrease the uncertainty of 235U(n,f) cross section in the keV region.
Collapse
|